Exploiting the Reverse Vaccinology Approach to Design Novel Subunit Vaccine against Ebola Virus

Md. Asad Ullah 1*, Bishajit Sarkar 1, Syed Sajidul Islam1

¹Department of Biotechnology and Genetic Engineering, Faculty of Biological Sciences, Jahangirnagar University, Savar, Dhaka, Bangladesh.

Corresponding author: Md. Asad Ullah*

Email of the corresponding author: <u>ullah1194@gmail.com</u>

Abstract

Ebola virus is a highly pathogenic RNA virus that causes haemorrhagic fever in human. With very

high mortality rate, Ebola virus is considered as one of the dangerous viruses in the world.

Although, the Ebola outbreaks claimed many lives in the past, no satisfactory treatment or vaccine

have been discovered yet to fight against Ebola. For this reason, in this study, various tools of

bioinformatics and immunoinformatics were used to design possible vaccines against Zaire Ebola

virus strain Mayinga-76. To construct the vaccine, three potential antigenic proteins of the virus,

matrix protein VP40, envelope glycoprotein and nucleoprotein were selected against which the

vaccines would be designed. The MHC class-I, MHC class-II and B-cell epitopes were determined

and after robust analysis through various tools and molecular docking analysis, three vaccine

candidates, designated as EV-1, EV-2 and EV-3, were constructed. Since the highly conserved

epitopes were used for vaccine construction, these vaccine constructs are also expected to be

effective on other strains of Ebola virus like strain Gabon-94 and Kikwit-95. Next, the molecular

docking study on these vaccine constructs were analyzed by molecular docking study and EV-1

emerged as the best vaccine construct. Later, molecular dynamics simulation study revealed the

good performances as well as good stability of the vaccine protein. Finally, codon adaptation and

in silico cloning were conducted to design a possible plasmid (pET-19b plasmid vector was used)

for large scale, industrial production of the EV-1 vaccine.

Keywords: Ebola virus, vaccine, immunoinformatics, bioinformatics, epitopes.

1. Introduction

Highly pathogenic Ebola viruses are non-segmented RNA viruses with high mortality rates that are a distinguishing feature of this human pathogen associated with Ebola haemorrhagic fever [1, 2]. The first recorded Ebola outbreaks were observed in Africa continent between June and November of 1976 and 53% (150 of 284 victims) was the mortality rate [3, 4]. Currently, there is no effective anti-viral treatment for the rapid progression of Ebola that allows little opportunity to develop natural immunity [5]. Ebola virus was subsequently defined as the prototype viruses of a new taxonomic family, filoviridae [6]. Ebola viruses are subdivided into four different subtypes, Zaire, Sudan, Cote d'Ivoire, and Reston. The latest discovery includes fourth African species of human-pathogenic ebola virus is the Bundibugyo Ebola virus strain. Beside of this, there are many more pathogenic strains includes Zaire Mayinga-76, Gabon-96, Kikwit-95, Eckron-76 etc. [7, 8, 9]. Among them Zaire Mayinga-76 strain and its vaccination study is performed in this in silico research article. Ebola hemorrhagic viral fever is a severe, often deadly disease of humans and nonhuman primates cause by non-segmented, single stranded RNA molecules of Ebola virus [10]. After the attack of Ebola virus, the immune system causes a systemic inflammatory response that causes the impairment of the vascular, coagulation, asthenia and arthralgia systems, which leads to multi-organ failure, resembling septic shock are some of the indicators of ebola virus infections [7]. In 2014, World Health Organization (WHO) organized an emergency meeting attended by 60 researchers and public health administrators to assess and produce safe and effective Ebola vaccines as soon as possible [11]. A recent study shows that a trial vaccine called recombinant vesicular stomatitis virus-Zaire Ebola virus (rVSV-ZEBOV), which has shown to be safe and protective against the Zaire strain is recommended for use in Ebola outbreaks [12]. However, despite a huge number of research and investigation, there is no effective and

satisfactory therapeutic clarification or vaccination has been invented so far against the Mayinga76 strain of Ebola virus. Even if an effective and safe vaccine can be produced, it is not likely to
be hundred percent effective to succeed in slowing down and stopping the current outbreak [13].

Development of an effective and safe Ebola virus vaccine has been hindered by a lack of
knowledge. In this study, an effort has been made to develop an effective Ebola vaccine using
various tools of bioinformatics, immunoinformatics and reverse vaccinology (**Figure 01**). Reverse
vaccinology is a process of vaccine development where the novel antigens are identified by
analyzing the genomic information of an organism or a virus. In reverse vaccinology, various tools
of in silico biology are used to discover the novel antigens by studying the genetic makeup of a
pathogen and the genes that could lead to good epitopes are determined. This method is a quick
easy and cost-effective way to design vaccine. Reverse vaccinology is successfully used for
designing vaccines for many viruses like zika virus, chikungunya virus etc. [14].




Figure 01. The flowchart of the procedures carried out in conducting the vaccine designing experiment.

2. Materials and methods:

The current experiment focuses on development of vaccines against the Zaire Ebola virus (strain

Mayinga-76).

2.1. Strain Identification and Selection

The strain of the Ebola virus strain Mayinga-76 was identified and selected by analyzing different

entries of the online server of National Center for Biotechnology Information or NCBI

(https://www.ncbi.nlm.nih.gov/).

2.2. Retrieval of the Protein Sequences

The viral envelope glycoprotein (accession number: Q05320), matrix protein VP40 (accession

number: Q05128) and nucleoprotein (accession number: P18272) were retrieved from the UniProt

Knowledgebase (UniProtKB) tool of the online server UniProt (https://www.uniprot.org/).

2.3. Antigenicity Prediction and Physicochemical Property Analysis of the Protein Sequences

The antigenicity of the protein sequences were predicted by online server for antigenicity analysis,

VaxiJen v2.0 (http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.htm), keeping the

threshold at 0.4 [15, 16, 17]. The various physicochemical properties of the selected protein

sequences were determined by ExPASy's online tool ProtParam

(https://web.expasy.org/protparam/) [18].

2.4. T-cell and B-cell Epitope Prediction

The T-cell and B-cell epitopes of the selected protein sequences were predicted using online

epitope prediction server Immune Epitope Database or IEDB (https://www.iedb.org/). The IEDB

database contains huge amount of experimental data on T-cell epitopes and antibodies. These data

are collected from various experiments that are carried on human, non-human primates and other animals. It is a server that allows robust analysis on various epitopes in the context of some tools: population coverage, conservation across antigens and clusters with similar sequences [19]. The MHC class-I restricted CD8+ cytotoxic T-lymphocyte (CTL) epitopes of the selected sequences were obtained using NetMHCpan EL 4.0 prediction method for HLA-A*11-01 allele. The MHC class-II restricted CD4+ helper T-lymphocyte (HTL) epitopes were obtained for HLA DRB1*04-01 allele using Sturniolo prediction method. Ten of the top twenty MHC class-I and MHC class-II epitopes were randomly selected based on their percentile scores and antigenicity scores (AS). Five random B-cell lymphocyte epitopes (BCL) were selected based on their length (the sequences that have ten amino acids or above were selected) and obtained using Bipipered linear epitope prediction method.

2.5. Transmembrane Topology and Antigenicity Prediction of the Selected Epitopes

The transmembrane topology of the selected epitopes were determined using the transmembrane topology of protein helices determinant, v2.0TMHMM server (http://www.cbs.dtu.dk/services/TMHMM/). The server predicts whether the epitope would be transmembrane or it would remain inside or outside of the membrane [20]. The antigenicity of the selected VaxiJen v2.0 epitopes predicted using (http://www.ddgwere pharmfac.net/vaxijen/VaxiJen/VaxiJen.htm), using the tumor model and threshold of 0.4.

2.6. Allergenicity and Toxicity Prediction of the Epitopes

The allergenicity of the selected epitopes were predicted using two online tools, AllerTOP v2.0 (https://www.ddg-pharmfac.net/AllerTOP/) and AllergenFP v1.0 (http://ddg-pharmfac.net/AllergenFP/). However, the results predicted by AllerTOP were given priority since

the server has better accuracy of 88.7% than AllergenFP server (87.9%) [21, 22]. The toxicity prediction of the selected epitopes were carried out using ToxinPred server (http://crdd.osdd.net/raghava/toxinpred/), using SVM (Swiss-Prot) based method, keeping all the parameters default.

2.7. Conservancy Prediction of the Selected Epitopes

The conservancy analysis of the selected epitopes were performed using the epitope conservancy analysis tool of IEDB server (https://www.iedb.org/conservancy/) (Vita et al., 2018). The sequence identity threshold was kept '>=50'. For the conservancy analysis of the selected epitopes of the Ebola virus strain Mayinga-76, the matrix protein VP40, envelope glycoprotein and nucleoprotein of Ebola virus strain Gabon-94 and Kikwit-95 were used for comparison along with the proteins of the Ebola virus strain Mayinga-76 itself (UniProt accession numbers: Q05128, Q2PDK5, Q77DJ6, Q05320, O11457, P87666, Q9QCE9, P18272 and O72142). Based on the antigenicity, allergenicity, toxicity and conservancy analysis, the best ligands were selected for the further analysis and vaccine construction. The T-cell epitopes that showed antigenicity, non-allergenicity, non-toxicity and high (more than 90%) conservancy and more than 50% minimum identity, were considered as the best epitopes. For B-cell epitope selection, only the antigenic and non-allergenic epitopes were taken for further analysis.

2.8. Cluster Analysis of the MHC Alleles

Cluster analysis of the MHC alleles helps to identify the alleles of the MHC class-I and class-II molecules that have similar binding specificities. The cluster analysis of the MHC alleles were carried out by online tool MHCcluster 2.0 (http://www.cbs.dtu.dk/services/MHCcluster/) [23]. During the analysis, the number of peptides to be included was kept 50,000, the number of

bootstrap calculations were kept 100 and all the HLA supertype representatives (MHC class-I) and

HLA-DR representatives (MHC class-II) were selected. For analyzing the MHC class-I alleles, the

NetMHCpan-2.8 prediction method was used. The output of the server generated results in the

form of MHC specificity tree and MHC specificity heat-map.

2.9. Generation of the 3D Structures of the Selected Epitopes

The 3D structures of the selected best epitopes were generated using online 3D generating tool

PEP-FOLD3 (http://bioserv.rpbs.univ-paris-diderot.fr/services/PEP-FOLD3/). The server is a tool

for generating de novo peptide 3D structure [24, 25, 26].

2.10. Molecular Docking of the Selected Epitopes

The molecular docking of the selected epitopes were carried out by online docking tool PatchDock

(https://bioinfo3d.cs.tau.ac.il/PatchDock/php.php). PatchDock tool has algorithms that divide the

Connolly dot surface representation of the molecules into concave, convex and flat patches. After

that the complementary patches are matched by the server for generating potential candidate

transformations. Next, each of the candidate transformations is evaluated by scoring function and

finally, an RMSD (root mean square deviation) clustering is applied to the candidate solutions for

discarding the redundant solutions. The top scored solutions are made the top ranked solutions by

the server. After docking by PatchDock, the docking results were refined and re-scored by

FireDock server (http://bioinfo3d.cs.tau.ac.il/FireDock/php.php). The FireDock server generates

global energies upon the refinement of the best solutions from the PatchDock server and ranks

them based on the generated global energies and the lowest global energy is always appreciable

and preferred [27, 28, 29, 30]. The molecular docking experiments were carried out using the

HLA-A*11-01 allele (PDB ID: 5WJL) and HLA DRB1*04-01 (PDB ID: 5JLZ) as receptors and

the ligands were the best selected MHC-I and MHC-II epitopes, respectively. The receptors were downloaded from the RCSB- Protein Data Bank (https://www.rcsb.org/) server. The best results were visualized using Discovery Studio Visualizer (Dassault Systèmes BIOVIA, Discovery Studio Visualizer, v19.1.0.1828 (2019), San Diego: Dassault Systèmes).

2.11. Vaccine Construction

Three possible vaccines were constructed against the selected Ebola virus strain Mayinga-76. For successful vaccine construction, the predicted CTL, HTL and BCL epitopes were conjugated together. All the vaccines were constructed maintaining the sequence: adjuvant, PADRE sequence, CTL epitopes, HTL epitopes and BCL epitopes. Three different adjuvant sequences were used for vaccine construction: beta defensin, L7/L12 ribosomal protein and HABA protein (M. tuberculosis, accession number: AGV15514.1). By acting as agonist, beta-defensin adjuvants stimulate the activation of the toll like receptors (TLRs): 1, 2 and 4. The L7/L12 ribosomal protein and HABA protein have the ability to activate TLR-4. During the vaccine construction, various linkers were used: EAAAK linkers were used to conjugate the adjuvant and PADRE sequence, GGGS linkers were used to attach the PADRE sequence with the CTL epitopes and the CTL epitopes with the other CTL epitopes, GPGPG linkers were used to connect the CTL epitopes with the HTL epitopes and also the HTL epitopes among themselves. The KK linkers were used for conjugating the HTL and BCL epitopes as well as the BLC epitopes among themselves [31, 32, 33, 34, 35, 36, 37]. The PADRE sequence improves the CTL response of the vaccines that contain the PADRE sequence [38]. Total three vaccines were constructed in the experiment.

2.12. Antigenicity, Allergenicity and Physicochemical Property Analysis

The antigenicity of the constructed vaccines were determined by the online server VaxiJen v2.0 (http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.htm). The threshold of the prediction was kept at 0.4 [15, 16, 17]. AlgPred (http://crdd.osdd.net/raghava/algpred/) and AllerTop v2.0 (https://www.ddg-pharmfac.net/AllerTOP/) were used for the prediction of the allergenicity of the vaccine constructs. The AlgPred server predicts the possible allergens based on similarity of known epitope of any of the known region of the protein [39]. MEME/MAST motif prediction approach is used in the allergenicity prediction of the vaccines by AlgPred. Moreover, various physicochemical properties of the vaccines were examined by the online server ProtParam (https://web.expasy.org/protparam/) [18].

2.13. Secondary and Tertiary Structure Prediction of the Vaccine Constructs

The secondary structures of the vaccine constructs were generated using online tool PRISPRED (http://bioinf.cs.ucl.ac.uk/psipred/). PRISPRED is a simple secondary structure generator that can be used to predict the transmembrane topology, transmembrane helix, fold and domain recognition etc. along with the secondary structure prediction [40, 41]. The PRISPRED 4.0 prediction method was used to predict the secondary structures of the vaccine constructs. The β -sheet structure of the vaccines determined another online tool, NetTurnP by v1.0 were (http://www.cbs.dtu.dk/services/NetTurnP/) [42]. The tertiary or 3D structures of the vaccines were generated using online tool RaptorX (http://raptorx.uchicago.edu/) server. The server is a fully annotated tool for the prediction of protein structure, the property and contact prediction, sequence alignment etc. [43, 44, 45].

2.14. 3D Structure Refinement and Validation

The 3D structures of the constructed vaccines were refined using online refinement tool 3Drefine (http://sysbio.rnet.missouri.edu/3Drefine/). The server is a quick, easy and efficient tool for protein structure refinement [46]. For each of the vaccine, the refined model 1 was downloaded for validation. The refined vaccine proteins were then validated by analyzing the Ramachandran plots which were generated using the online tool, PROCHECK (https://servicesn.mbi.ucla.edu/PROCHECK/) [47, 48].

2.15. Vaccine Protein Disulfide Engineering

The vaccine protein disulfide engineering was carried out by online tool Disulfide by Design 2 v12.2 (http://cptweb.cpt.wayne.edu/DbD2/). The server predicts the possible sites within a protein structure that may undergo disulfide bond formation [49]. When engineering the disulfide bonds, the intra-chain, inter-chain and C_{β} for glycine residue were selected. The χ_3 angle was kept -87° or +97° ±5 and C_{α} - C_{β} - S_{γ} angle was kept 114.6° ±10, during the experiment.

2.16. Protein-Protein Docking

In protein-protein docking, the constructed Ebola virus vaccines were analyzed by docking against various MHC alleles and toll like receptors (TLR). One best vaccine would be selected based on its superior performances in the docking experiment. When viral infections occur, the viral particles or antigens are recognized by the MHC complex. The various segments of the MHC molecules are encoded by different alleles. For this reason, the vaccines should have good binding affinity with these MHC portions that are encoded by different alleles [50]. All the vaccine constructs were docked against the selected MHC alleles to test their binding affinity. In this experiment, the vaccines constructs were docked against DRB1*0101 (PDB ID: 2FSE),

DRB3*0202 (PDB ID: 1A6A), DRB5*0101 (PDB ID: 1H15), DRB3*0101 (PDB ID: 2Q6W), DRB1*0401 (PDB ID: 2SEB), and DRB1*0301 (PDB ID: 3C5J). Moreover, studies have proved that TLR-8, present on the immune cells, are responsible for mediating the immune responses against the RNA viruses and TLR-3 of the immune cells mediates immune responses against the DNA viruses [51, 52]. The ebola virus is a RNA virus [53]. For this reason, the vaccine constructs of ebola virus were also docked against TLR-8 (PDB ID: 3W3M). The protein-protein docking was carried out using various online docking tools. The docking was carried out three times by three different online servers for improving the accuracy of the docking. First, the docking was carried out by ClusPro 2.0 (https://cluspro.bu.edu/login.php). The server ranks the clusters of docked complexes based on their center and lowest energy scores. However, these scores do not represent the actual binding affinity of the proteins with their targets [54, 55, 56]. The bonding affinity (ΔG in kcal mol⁻¹) of docked complexes were generated by PRODIGY tool of HADDOCK webserver (https://haddock.science.uu.nl/). The lower the binding energy generated by the server, the higher the binding affinity [57, 58, 59]. Moreover, the docking was again performed by PatchDock (https://bioinfo3d.cs.tau.ac.il/PatchDock/php.php) and later refined and re-scored by FireDock server (http://bioinfo3d.cs.tau.ac.il/FireDock/php.php). The FireDock server ranks the docked complexes based on their global energy and the lower the score, the better the result [27, 28, 29, 301 docking performed HawkDock Later, the was using server (http://cadd.zju.edu.cn/hawkdock/). The Molecular Mechanics/Generalized Born Surface Area (MM-GBSA) study was also carried out using HawkDock server. According to the server, the lower scores and lower energy corresponds to better scores [60, 61, 62, 63]. The HawkDock server generates several models of docked complex and ranks them by assigning HawkDock scores in the ascending order. For each of the vaccines and their respective targets, the score of model 1 was

taken for analysis. Furthermore, the model 1 of every complex was analyzed for MM-GBSA study.

From the docking experiment, one best vaccine was selected for further analysis. The docked

structures were visualized by PyMol tool [64].

2.17. Molecular Dynamic Simulation

The molecular dynamics simulation study was conducted for the best selected vaccine, by the

online server iMODS (http://imods.chaconlab.org/). iMODS server is a fast, online, user-friendly

and effective molecular dynamics simulation server that can be used efficiently to investigate the

structural dynamics of the protein complexes. The server provides the values of deformability, B-

factor (mobility profiles), eigenvalues, variance, co-variance map and elastic network. For a

protein complex, the deformability depends on the ability to deform at each of its amino acid. The

eigenvalue is related with the energy that is required to deform the given structure and the lower

the eigenvalue, the easier the deformability of the complex. The eigenvalue also represents the

motion stiffness of the protein complex. The server is a fast and easy tool for determining and

measuring the protein flexibility [65, 66, 67, 68, 69]. For analysing the molecular dynamics

simulation of the EV-1-TLR-8 docked complex was used. The docked PDB files were uploaded

to the iMODS server and the results were displayed keeping all the parameters as default.

2.18. Codon Adaptation and In Silico Cloning

In codon adaptation, the best selected vaccine protein was reverse transcribed to the possible DNA

sequence. The DNA sequence should encode the target vaccine protein. After that, the reverse

transcribed DNA sequence was adapted according to the desired organism, so that the cellular mechanisms of that specific organism could use the codons of the adapted DNA sequences efficiently and provide better production of the desired product. Codon adaptation is a necessary step of in silico cloning because the same amino acid can be encoded by different codons in different organisms (codon biasness). Moreover, the cellular mechanisms of an organism may be different from another organism and a codon for a specific amino acid may not work in another organism. For this reason, codon adaptation can predict the suitable codon that can encode a specific amino acid in a specific organism [70, 71]. The predicted protein sequences of the best selected vaccines were used for codon adaptation by the Java Codon Adaptation Tool or JCat server (http://www.jcat.de/) [70]. Eukaryotic E. coli strain K12 was selected and rho-independent transcription terminators, prokaryotic ribosome binding sites and SgrA1 and SphI cleavage sites of restriction enzymes, were avoided. In the JCat server, the protein sequences were reverse translated to the optimized possible DNA sequences. The optimized DNA sequences were taken and SgrA1 and SphI restriction sites were conjugated at the N-terminal and C-terminal sites, respectively. Next, the SnapGene [72] restriction cloning module was used to insert the new adapted DNA sequences between SgrA1 and SphI of pET-19b vector.

3. Results

3.1. Identification, Selection and Retrieval of Viral Protein Sequences

The Zaire Ebola virus, strain Mayinga-76 was identified selected from the NCBI (https://www.ncbi.nlm.nih.gov/). Three proteins from the viral structures were selected for the possible vaccine construction. These proteins were: envelope glycoprotein (accession number: Q05320), matrix protein VP40 (accession number: Q05128) and nucleoprotein (accession number: P18272). The protein sequences were retrieved from the online server, UniProt (https://www.uniprot.org/). The protein sequences in fasta format:

>sp|Q05128|VP40_EBOZM Matrix protein VP40 OS=Zaire ebolavirus (strain Mayinga-76)
OX=128952 GN=VP40 PE=1 SV=1

MRRVILPTAPPEYMEAIYPVRSNSTIARGGNSNTGFLTPESVNGDTPSNPLRPIADDTIDH
ASHTPGSVSSAFILEAMVNVISGPKVLMKQIPIWLPLGVADQKTYSFDSTTAAIMLASYTI
THFGKATNPLVRVNRLGPGIPDHPLRLLRIGNQAFLQEFVLPPVQLPQYFTFDLTALKLIT
QPLPAATWTDDTPTGSNGALRPGISFHPKLRPILLPNKSGKKGNSADLTSPEKIQAIMTSL
QDFKIVPIDPTKNIMGIEVPETLVHKLTGKKVTSKNGQPIIPVLLPKYIGLDPVAPGDLTM
VITQDCDTCHSPASLPAVIEK

>sp|Q05320|VGP_EBOZM Envelope glycoprotein OS=Zaire ebola virus (strain Mayinga-76)
OX=128952 GN=GP PE=1 SV=1

MGVTGILQLPRDRFKRTSFFLWVIILFQRTFSIPLGVIHNSTLQVSDVDKLVCRDKLSSTN QLRSVGLNLEGNGVATDVPSATKRWGFRSGVPPKVVNYEAGEWAENCYNLEIKKPDG SECLPAAPDGIRGFPRCRYVHKVSGTGPCAGDFAFHKEGAFFLYDRLASTVIYRGTTFAE GVVAFLILPQAKKDFFSSHPLREPVNATEDPSSGYYSTTIRYQATGFGTNETEYLFEVDN

LTYVQLESRFTPQFLLQLNETIYTSGKRSNTTGKLIWKVNPEIDTTIGEWAFWETKKNLT
RKIRSEELSFTVVSNGAKNISGQSPARTSSDPGTNTTTEDHKIMASENSSAMVQVHSQGR
EAAVSHLTTLATISTSPQSLTTKPGPDNSTHNTPVYKLDISEATQVEQHHRRTDNDSTAS
DTPSATTAAGPPKAENTNTSKSTDFLDPATTTSPQNHSETAGNNNTHHQDTGEESASSG
KLGLITNTIAGVAGLITGGRRTRREAIVNAQPKCNPNLHYWTTQDEGAAIGLAWIPYFGP
AAEGIYIEGLMHNQDGLICGLRQLANETTQALQLFLRATTELRTFSILNRKAIDFLLQRW
GGTCHILGPDCCIEPHDWTKNITDKIDQIIHDFVDKTLPDQGDNDNWWTGWRQWIPAGI
GVTGVIIAVIALFCICKFVF

>sp|P18272|NCAP_EBOZM Nucleoprotein OS=Zaire ebola virus (strain Mayinga-76)
OX=128952 GN=NP PE=1 SV=2

MDSRPQKIWMAPSLTESDMDYHKILTAGLSVQQGIVRQRVIPVYQVNNLEEICQLIIQAF
EAGVDFQESADSFLLMLCLHHAYQGDYKLFLESGAVKYLEGHGFRFEVKKRDGVKRLE
ELLPAVSSGKNIKRTLAAMPEEETTEANAGQFLSFASLFLPKLVVGEKACLEKVQRQIQV
HAEQGLIQYPTAWQSVGHMMVIFRLMRTNFLIKFLLIHQGMHMVAGHDANDAVISNSV
AQARFSGLLIVKTVLDHILQKTERGVRLHPLARTAKVKNEVNSFKAALSSLAKHGEYAP
FARLLNLSGVNNLEHGLFPQLSAIALGVATAHGSTLAGVNVGEQYQQLREAATEAEKQ
LQQYAESRELDHLGLDDQEKKILMNFHQKKNEISFQQTNAMVTLRKERLAKLTEAITAA
SLPKTSGHYDDDDDIPFPGPINDDDNPGHQDDDPTDSQDTTIPDVVVDPDDGSYGEYQS
YSENGMNAPDDLVLFDLDEDDEDTKPVPNRSTKGGQQKNSQKGQHIEGRQTQSRPIQN
VPGPHRTIHHASAPLTDNDRRNEPSGSTSPRMLTPINEEADPLDDADDETSSLPPLESDDE
EQDRDGTSNRTPTVAPPAPVYRDHSEKKELPQDEQQDQDHTQEARNQDSDNTQSEHSF

EEMYRHILRSQGPFDAVLYYHMMKDEPVVFSTSDGKEYTYPDSLEEEYPPWLTEKEAM

NEENRFVTLDGQQFYWPVMNHKNKFMAILQHHQ

3.2. Antigenicity Prediction and Physicochemical Property Analysis of the Protein Sequences

VaxiJen v2.0 (http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.htm) and ProtParam

(https://web.expasy.org/protparam/) servers were used for antigenicity analysis and

physicochemical property prediction of the selected protein sequences (Table 01). In the

physicochemical property analysis, the number of amino acids, the molecular weights, theoretical

pI, extinction coefficients, half-lives, instability indexes, aliphatic indexes and grand average of

hydropathicity (GRAVY) of the three proteins were predicted. All the three selected protein

sequences showed good level of antigenicity. The matrix protein VP40 had the lowest molecular

weight of 35182.83 and only envelope glycoprotein was stable according to the prediction. All of

the three proteins had 30 hours of half-life in mammalian cells. The matrix protein VP40 also

showed the highest theoretical pI, aliphatic index and GRAVY values (**Table 01**).

3.3. T-cell and B-cell Epitope Prediction and Topology Determination of the Epitopes

The T-cell epitopes of MHC class-I of the three proteins were determined by NetMHCpan EL 4.0

prediction method of the IEDB (https://www.iedb.org/) server keeping the sequence length 9. The

server generated over 100 such epitopes. However, based on analyzing the antigenicity scores (AS)

and percentile scores, for each epitope, ten potential epitopes from the top twenty epitopes were

selected randomly for antigenicity, allergenicity, toxicity and conservancy tests. The server ranks

the predicted epitopes based on the ascending order of percentile scores. The lower the percentile,

the better the binding affinity. The T-cell epitopes of MHC class-II (HLA DRB1*04-01 allele) of

the proteins were also determined by IEDB (https://www.iedb.org/) server, where the Sturniolo prediction methods was used. For each protein, ten of the top twenty epitopes were selected randomly for further analysis. Moreover, the B-cell epitopes of the proteins were selected using Bipipered linear epitope prediction method of the IEDB (https://www.iedb.org/) server and epitopes were selected based on their higher lengths (**Figure 02**). The topology of the selected epitopes were determined by TMHMM v2.0 server (http://www.cbs.dtu.dk/services/TMHMM/). **Table 02** and **Table 03** list the potential T-cell epitopes of matrix protein VP40, **Table 04** and **Table 05** list the potential T-cell epitopes of envelope glycoprotein, **Table 06** and **Table 07** list the potential T-cell epitopes of nucleoprotein and **Table 08** list the potential B-cell epitopes with their respective topologies.

3.4. Antigenicity, allergenicity, toxicity and conservancy analysis

In the antigenicity, allergenicity, toxicity and conservancy analysis, the T-cell epitopes that were found to be highly antigenic as well as non-allergenic, non-toxic, had minimum identity of over 50% and had conservancy of over 90% as well as antigenic and non-allergenic B-cell epitopes were selected for further analysis and vaccine construction. Among the ten selected MHC class-I epitopes and ten selected MHC class-II epitopes of matrix protein VP40, total six epitopes (three epitopes from each of the category) were selected based on the mentioned criteria: MVNVISGPK, ILLPNKSGK, GISFHPKLR, QKTYSFDSTTAA, KTYSFDSTTAAI and WLPLGVADQKTY. On the other hand, among the ten selected MHC class-I epitopes and ten selected MHC class-II epitopes of envelope glycoprotein, total six epitopes (three epitopes from each of the category) were selected based on the mentioned criteria: STHNTPVYK, ATQVEQHHR, SGYYSTTIR, TPQFLLQLNETI, PQFLLQLNETIY and FLLQLNETIYTS. Moreover, like these proteins, six epitopes that obeyed the mentioned criteria, were selected for further analysis from the

nucleoprotein epitopes: TVLDHILQK, VVFSTSDGK, QTNAMVTLR, SFLLMLCLHHAY, FLLMLCLHHAYQ and VVFSTSDGKEYT. For the selection of the B-cell epitopes, the highly antigenic and non-allergenic sequences were taken for vaccine construction. Three epitopes from each of the protein category were selected. For this reason, total nine epitopes B-cell epitopes were selected for vaccine construction, since they obeyed the selection criteria. (**Table 02**, **Table 03**, **Table 04**, **Table 05**, **Table 06**, **Table 07** and **Table 08**).

Table 01. The antigenicity and physicochemical property analysis of the selected viral proteins.

Name of	Antigenicity	Total	Molecular	Theoretical	Ext.	Est. half-	Instability	Aliphatic	Grand
the	(threshold	amino	weight	pI	coefficient	life (in	index	index	average
protein	0.4)	acids			(in M ⁻¹ cm ⁻	mammalia			of
sequence					1)	n cell)			hydropat
									hicity
									(GRAVY
)
Matrix	0.5692	326	35182.83	8.76	20065	30 hours	40.39	96.32	-0.052
protein	(bacteria),						(unstable)		
VP40	0.4598								
	(tumor),								
	0.5496								
	(parasite)								
Envelope	0.5852	676	74464.46	6.16	74464.46	30 hours	38.36 (stable)	75.77	-0.380
glycoprote	(bacteria),								
in	0.4933								
	(tumor),								
	0.5364								
	(parasite)								
Nucleopro	0.5315	739	83286.68	4.98	53415	30 hours	50.31	74.32	-0.691
tein	(bacteria),						(unstable)		
	0.5442								
	(tumor),								
	0.4692								
	(parasite)								

Table 02. MHC class-I epitope prediction and topology, antigenicity, allergenicity, toxicity and conservancy analysis of the epitopes of matrix protein VP40.

Matrix protein VP40													
Epitope	Start	End	Topology	AS	Percentile scores	Antig enicit y (tumo r, thresh old 0.4)	Allergen	Toxicity	Conser	Minimum identity			
ASLPAVIEK	318	326	Outside	0.972	0.01	Antige	Allergen	Non-toxic	100%	100%			
FTFDLTALK	172	180	Outside	0.881	0.02	Non- antige	Allergen	Non-toxic	100%	100%			
MVNVISGPK	78	86	Inside	0.469	0.37	Antige n	Non- allergen	Non-toxic	100%	100%			
SADLTSPEK	228	236	Outside	0.391	0.52	Non- antige	Non- allergen	Non-toxic	88.89%	100%			
TLVHKLTGK	266	274	Inside	0.363	0.57	Non- antige	Allergen	Non-toxic	100%	100%			
ILLPNKSGK	216	224	Outside	0.358	0.58	Antige n	Non- allergen	Non-toxic	100%	100%			

IMTSLQDFK	240	258	Inside	0.356	0.58	Antige	Allergen	Non-toxic	88.89%	100%
						n				
LVHKLTGKK	267	275	Inside	0.276	0.82	Antige	Allergen	Non-toxic	100%	100%
						n				
MLASYTITH	116	124	Inside	0.131	1.6	Non-	Non-	Non-toxic	100%	100%
						antige	allergen			
						n				
GISFHPKLR	206	214	Outside	0.127	1.7	Antige	Non-	Non-toxic	100%	100%
						n	allergen			

Table 03. MHC class-II epitope prediction and topology, antigenicity, allergenicity, toxicity and conservancy analysis of the epitopes of matrix protein VP40.

Matrix protein VP40													
Start	End	Topology	AS	Percent	Antigenici tv (tumor	Allergen	Toxicity	Conser	Minimum identity				
				scores	threshold	icity		vancy	identity				
171	182	Outside	3.80	1.20	Non-	Non-	Non-toxic	100%	100%				
170	181	Outside	3.80	1.20	Non- antigen	Non-allergen	Non-toxic	100%	100%				
169	180	Outside	3.80	1.20	Antigen	Allergen	Non-toxic	100%	100%				
103	114	Inside	3.70	1.40	Antigen	Non- allergen	Non-toxic	100%	100%				
104	115	Inside	3.70	1.40	Antigen	Non- allergen	Non-toxic	100%	100%				
93	104	Outside	3.50	1.90	Antigen	Allergen	Non-toxic	100%	100%				
94	105	Outside	3.50	1.90	Antigen	Allergen	Non-toxic	100%	100%				
95	106	Outside	3.50	1.90	Antigen	Non- allergen	Non-toxic	100%	100%				
17	28	Inside	3.28	2.40	Antigen	Allergen	Non-toxic	100%	100%				
19	30	Inside	3.28	2.40	Antigen	Allergen	Non-toxic	100%	100%				
	171 170 169 103 104 93 94 95	171 182 170 181 169 180 103 114 104 115 93 104 94 105 95 106	Start End Topology 171 182 Outside 170 181 Outside 169 180 Outside 103 114 Inside 104 115 Inside 93 104 Outside 94 105 Outside 95 106 Outside 17 28 Inside	Start End Topology AS 171 182 Outside 3.80 170 181 Outside 3.80 169 180 Outside 3.80 103 114 Inside 3.70 104 115 Inside 3.70 93 104 Outside 3.50 94 105 Outside 3.50 95 106 Outside 3.50 17 28 Inside 3.28	Start End Topology AS Percent ile scores 171 182 Outside 3.80 1.20 170 181 Outside 3.80 1.20 169 180 Outside 3.80 1.20 103 114 Inside 3.70 1.40 104 115 Inside 3.70 1.40 93 104 Outside 3.50 1.90 94 105 Outside 3.50 1.90 95 106 Outside 3.50 1.90 17 28 Inside 3.28 2.40	Start	Start	Start	Start				

Table 04. MHC class-I epitope prediction and topology, antigenicity, allergenicity, toxicity and conservancy analysis of the epitopes of envelope glycoprotein.

Envelope glycoprotein													
Epitope	Start	End	Topology	AS	Percentile scores	Antigeni city (tumor, threshol d 0.4)	Allergen	Toxicity	Conser	Minimum			
STHNTPVYK	387	395	Inside	0.964	0.01	Antigeni c	Non- allergeni	Non-toxic	100%	100%			
RTFSILNRK	580	588	Inside	0.947	0.01	Non- antigen	Non- allergen	Non-toxic	100%	100%			
ATDVPSATK	76	84	Inside	0.872	0.03	Antigen	Allergen	Non-toxic	100%	100%			
KAIDFLLQR	588	596	Inside	0.864	0.04	Non- antigen	Allergen	Non-toxic	100%	100%			
QIIHDFVDK	625	633	Inside	0.465	0.37	Non- antigen	Non- allergen	Non-toxic	100%	100%			
ATQVEQHHR	401	409	Inside	0.314	0.69	Antigeni c	Non- allergeni c	Non-toxic	100%	100%			
CAGDFAFHK	147	155	Inside	0.311	0.70	Non- antigen	Allergen	Non-toxic	100%	100%			
TSPQSLTTK	373	381	Inside	0.295	0.76	Antigen	Allergen	Non-toxic	66.67%	44.44%			
SGYYSTTIR	211	219	Inside	0.224	1.00	Antigen	Non- allergen	Non-toxic	100%	100%			
KLSSTNQLR	56	64	Inside	0.228	0.98	Antigen	Allergen	Non-toxic	100%	100%			

Table 05. MHC class-II epitope prediction and topology, antigenicity, allergenicity, toxicity and conservancy analysis of the epitopes of envelope glycoprotein.

Envelope glycoprotein													
Epitope	Start	End	Topology	AS	Percent ile scores	Antigenicit y (tumor, threshold 0.4)	Allergen icity	Toxicity	Conser	Minimum			
TPQFLLQLNETI	249	260	Outside	4.00	0.93	Antigen	Non- allergen	Non-toxic	100%	100%			
QFLLQLNETIYT	251	262	Outside	4.00	0.93	Antigen	Allergen	Non-toxic	100%	91.67%			
VYKLDISEATQV	393	404	Inside	3.50	1.90	Antigen	Allergen	Non-toxic	100%	100%			
VIHNSTLQVSDV	37	48	Inside	3.10	3.00	Antigen	Allergen	Non-toxic	100%	100%			
PQFLLQLNETIY	250	261	Outside	4.00	0.93	Antigen	Non- allergen	Non-toxic	100%	100%			
FLLQLNETIYTS	252	263	Outside	4.00	0.93	Antigen	Non- allergen	Non-toxic	100%	100%			
TPVYKLDISEAT	391	402	Outside	3.50	1.90	Non- antigen	Allergen	Non-toxic	100%	100%			
LGVIHNSTLQVS	35	46	Outside	3.10	3.00	Antigen	Allergen	Non-toxic	100%	100%			
GVIHNSTLQVSD	36	47	Outside	3.10	3.00	Antigen	Allergen	Non-toxic	100%	100%			
QLFLRATTELRT	570	580	Inside	2.80	3.90	Non- antigen	Non- allergen	Non-toxic	100%	100%			

Table 06. MHC class-I epitope prediction and topology, antigenicity, allergenicity, toxicity and conservancy analysis of the epitopes of nucleoprotein.

Nucleoprotein													
Epitope	Start	End	Topology	AS	Percent ile scores	Antigenicit y (tumor, threshold 0.4)	Allergeni	Toxicity	Conser	Minimum			
TVLDHILQK	249	257	Inside	0.981	0.01	Antigen	Non- allergen	Non-toxic	100%	100%			
AVLYYHMMK	664	672	Inside	0.865	0.03	Antigen	Allergen	Non-toxic	100%	100%			
VVFSTSDGK	676	684	Outside	0.788	0.08	Antigen	Non- allergen	Non-toxic	100%	100%			
KILMNFHQK	374	382	Inside	0.704	0.14	Non-antigen	Allergen	Non-toxic	100%	100%			
AVSSGKNIK	123	131	Inside	0.643	0.02	Antigen	Allergen	Non-toxic	100%	100%			
VTLDGQQFY	713	721	Outside	0.568	0.26	Non-antigen	Non- allergen	Non-toxic	100%	100%			
QTNAMVTLR	390	398	Inside	0.512	0.32	Antigen	Non- allergen	Non-toxic	100%	100%			
HGFRFEVKK	102	110	Inside	0.310	0.71	Antigen	Allergen	Non-toxic	100%	100%			
SFASLFLPK	152	160	Outside	0.306	0.72	Non-antigen	Non- allergen	Non-toxic	100%	100%			
VSSGKNIKR	124	132	Inside	0.264	0.85	Antigen	Allergen	Non-toxic	100%	100%			

Table 07. MHC class-II epitope prediction and topology, antigenicity, allergenicity, toxicity and conservancy analysis of the epitopes of nucleoprotein.

Nucleoprotein													
Epitope	Start	End	Topology	AS	Percent ile scores	Antigenicit y (tumor, threshold 0.4)	Allergen	Toxicity	Conser	Minimum			
VIFRLMRTNFLI	199	210	Inside	5.60	0.07	Non- antigen	Non- allergen	Non-toxic	100%	100%			
IFRLMRTNFLIK	200	211	Inside	5.60	0.07	Non- antigen	Non- allergen	Non-toxic	100%	100%			
FRLMRTNFLIKF	201	212	Inside	5.60	0.07	Antigen	Allergen	Non-toxic	100%	100%			
SFLLMLCLHHAY	72	83	Outside	3.68	1.50	Antigen	Non-	Non-toxic	100%	100%			
FLLMLCLHHAYQ	73	84	Outside	3.68	1.50	Antigen	Non-	Non-toxic	100%	100%			
DSFLLMLCLHHA	71	82	Outside	3.68	1.50	Antigen	Allergen	Non-toxic	100%	100%			
VVFSTSDGKEYT	676	687	Outside	3.10	2.90	Antigen	Non- allergen	Non-toxic	100%	100%			
DEPVVFSTSDGK	673	684	Outside	3.10	2.90	Antigen	Allergen	Non-toxic	100%	100%			
PVYRDHSEKKEL	609	620	Inside	2.90	3.60	Non- antigen	Non- allergen	Non-toxic	100%	91.67%			
PAPVYRDHSEKK	607	618	Inside	2.90	3.60	Non- antigen	Non- allergen	Non-toxic	100%	91.67%			

Table 08. B-cell epitope prediction and antigenicity, allergenicity and topology prediction of the epitopes of the three selected proteins.

Matri	ix protein VI	P40		F	Envelope gl	ycoproteir	1		Nucleoprotein		
Epitope	Antigeni	All	Торо	Epitope	Antigen	Allerg	Topolog	Epitope	Antigenicity	Allergen	Topol
	city	erg	logy		icity	enicity	y		(tumor,	icity	ogy
	(tumor,	eni			(tumor,				threshold 0.4)		
	threshold	cit			thresho						
	0.4)	y			ld 0.4)						
RSNSTIARGG	Antigen	No	Insid	NGVATD	Antigen	Non-	Outside	AMPEEETTE	Antigen	Non-	Inside
NSNTGFLTPE		n-	e	VPSATK		allerge		ANA		allergen	
SVNGDTPSN		alle		RWGFRS		n					
PLRPIADDTI		rge		GVPPKV							
DHASHTPGS		n		VNYEAG							
V				EWAE							
ADQKTYSFD	Non-	All	Insid	YTSGKR	Antigen	Allerge	Inside	VGEQYQQLR	Antigen	Allergen	Inside
S	antigen	erg	e	SNTT		n		EAATEAEKQ			
		en						LQQYAESR			
NKSGKKGNS	Antigen	No	Insid	KKPDGS	Antigen	Non-	Outside	APLTDNDRR	Antigen	Non-	Inside
ADLTSPEK		n-	e	ECLPAA		allerge		NEPSGSTSPR		allergen	
		alle		PDGIRG		n		ML			
		rge									
		n									
KKVTSKNGQ	Antigen	No	Insid	NGAKNI	Antigen	Non-	Inside	VVFSTSDGKE	Antigen	Non-	Outsid
P		n-	e	SGQSPA		allerge		YTYPDSLEEE		allergen	e
		alle		RTSSDP		n		YPPWLTEKE			
		rge		GTNTTT				AMNE			
		n		EDH							
LPAATWTDD	Antigen	All	Outsi	KTLPDQ	Antigen	Allerge	Outside	SLPKTSGHYD	Non-antigen	Allergen	Outsid
TPTGSNGAL		erg	de	GDNDN		n		DDDDIPFPGPI			e
R		en		WWT				NDDDNPGHQ			

		DDDPTDSQD		
		TTIPDVVVDP		
		DDGSYGEYQ		
		SYSENGMNA		
		P		




Figure 02. Figure showing the graphs of the B-cell epitope prediction of the three selected proteins of Ebola virus strain Mayinga-76, using Bipipered linear epitope prediction method. Here, (a) is the graph of epitope prediction for matrix protein VP40, (b) is the graph of epitope prediction for envelope glycoprotein and (c) is the graph of epitope prediction for nucleoprotein.

3.5. Cluster Analysis of the MHC Alleles

The cluster analysis of the possible MHC class-I and MHC class-II alleles that may interact with the predicted epitopes were performed by online tool MHCcluster 2.0 (http://www.cbs.dtu.dk/services/MHCcluster/). The tool generates the clusters of the alleles in phylogenetic manner. **Figure 03** illustrates the outcome of the experiment where the red zone indicates strong interaction and the yellow zone corresponds to weaker interaction.

3.6. Generation of the 3D Structures of the Epitopes and Peptide-Protein Docking

All the T-cell epitopes were subjected to 3D structure generation by the PEP-FOLD3 server. The 3D structures were generated for peptide-protein docking. The docking was performed to find out, whether all the epitopes had the ability to bind with the MHC class-I and MHC class-II molecule. The selected epitopes were docked against the HLA-A*11-01 allele (PDB ID: 5WJL) and HLA DRB1*04-01 (PDB ID: 5JLZ). The docking was performed using PatchDock online docking tool and then the results were refined by FireDock online server. Among the MHC class-I epitopes of matrix protein VP40, GISFHPKLR showed the best result with the lowest global energy of -31.68. Among the MHC class-I epitopes of envelope glycoprotein, SGYYSTTIR generated the lowest and best global energy score of -42.87. QTNAMVTLR generated the best global energy score of -45.40 of the MHC class-I epitopes of nucleoprotein. Among the MHC class-II epitopes of matrix protein VP40, KTYSFDSTTAAI generated the best global energy score of -24.32 and TPOFLLQLNETI generated the lowest global energy of -2.80 and VVFSTSDGKEYT generated the lowest global energy of -12.06, among the MHC class-II epitopes of envelope glycoprotein and nucleoprotein, respectively (Table 09). Figure 04 illustrates the interaction between the best docked epitopes with their respective targets.




Figure 03. The results of the MHC cluster analysis. Here, (a) is the heat map of MHC class-I cluster analysis, (b) is the tree map of MHC class-I cluster analysis, (c) is the heat map of MHC class-II cluster analysis. The cluster analysis was carried out using onine server MHCcluster 2.0 (http://www.cbs.dtu.dk/services/MHCcluster/).

Table 09. Results of molecular docking analysis of the selected epitopes.

Name	Epitope	МНС	Global	Hydrogen	Epitope	MHC allele	Global	Hydrogen
of the		allele	energy	bond energy			energy	bond energy
protein								
Matrix	MVNVISGP	HLA-	-27.34	-0.63	QKTYSFDSTTAA	HLA	-3.45	0.00
protein	K	A*11-01				DRB1*04-01		
VP40	ILLPNKSG	allele	-31.35	-0.94	KTYSFDSTTAAI	(PDB ID:	-24.32	-3.49
	K	(PDB				5JLZ)		
	GISFHPKL	ID:	-31.68	-3.76	WLPLGVADQKTY	_	-17.07	-0.78
	R	5WJL)						
Envelo	STHNTPVY		-37.49	-3.52	TPQFLLQLNETI		-2.80	-4.87
pe	K							
glycopr	ATQVEQH		-30.49	-3.87	PQFLLQLNETIY		-0.39	0.00
otein	HR							
	SGYYSTTI		-42.87	-4.99	FLLQLNETIYTS	_	-1.78	-3.22
	R							
Nucleo	TVLDHILQ		-29.99	-0.87	SFLLMLCLHHAY		-8.47	-2.24
protein	K							
	VVFSTSDG		-34.14	-3.19	FLLMLCLHHAYQ	-	-4.62	0.00
	K							
	QTNAMVT		-45.40	-3.31	VVFSTSDGKEYT	-	-12.06	-0.28
	LR							




Figure 04. Figure showing the interactions between the best epitopes from the three proteins and their respective receptors. Here, (a) is the interaction between GISFHPKLR and MHC class-I, (b) is the interaction between SGYYSTTIR and MHC class-I, (c) is the interaction between QTNAMVTLR and MHC class-I molecule, (d) is the interaction between KTYSFDSTTAAI and MHC class-II, (e) is the interaction between TPQFLLQLNETI and MHC class-II, (f) is the interaction between VVFSTSDGKEYT and MHC class-II molecule. The interactions were visualized by Discovery Studio Visualizer.

3.7. Vaccine Construction

After successful docking, three vaccines were constructed, that could be used effectively to fight against ebola virus strain Mayinga-76. For vaccine constructions, three different adjuvants were used to construct three different vaccine for each of the viruses: beta defensin, L7/L12 ribosomal protein and HABA protein, were used. PADRE sequence was also used for vaccine construction. Three different vaccine constructs differed from each other only in their adjuvant sequences. To construct a vaccine, first the adjuvant sequence was conjugated with the PADRE sequence by EAAAK linker, then the PADRE sequence was added to the CTL epitopes by GGGS linkers, the CTL epitopes were also conjugated with each other by the GGGS linkers. Next, the HTL epitopes were conjugated by GPGPG linkers and the BCL epitopes were linked by KK linkers. Each vaccine construct was ended by an additional GGGS linker. The newly constructed vaccines were designated as: EV-1, EV-2 and EV-3 (Table 10).

Table 10. List of the vaccines constructed for ebola virus strain Mayinga-76.

Name of the	Vaccine constructs	Number
vaccines		of amino
		acids
Ebola	EAAAKGIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKKEAAAKAKFVAAWTLKAAAGG	596
vaccine-1	GSMVNVISGPKGGGSILLPNKSGKGGGSGISFHPKLRGGGSSTHNTPVYKGGGSATQVEQHHRGGGSSGYY	390
(EV-1)	STTIRGGGSTVLDHILQKGGGSVVFSTSDGKGGGSQTNAMVTLRGPGPGQKTYSFDSTTAAGPGPGKTYSF	
	DSTTAAIGPGPGWLPLGVADQKTYGPGPGTPQFLLQLNETIGPGPGPQFLLQLNETIYGPGPGFLLQLNETIY	
	TSGPGPGSFLLMLCLHHAYGPGPGFLLMLCLHHAYQGPGPGVVFSTSDGKEYTKKRSNSTIARGGNSNTGF	
	LTPESVNGDTPSNPLRPIADDTIDHASHTPGSV KK NKSGKKGNSADLTSPEK KK KKVTSKNGQP KK NGVATD	
	VPSATKRWGFRSGVPPKVVNYEAGEWAE KK KKPDGSECLPAAPDGIRG KK NGAKNISGQSPARTSSDPGTN	
	TTTEDH KK AMPEEETTEANA KK APLTDNDRRNEPSGSTSPRML KK VVFSTSDGKEYTYPDSLEEEYPPWLTE	
	KEAMNE KK AKFVAAWTLKAAA GGGS	
Ebola	EAAAK MAKLSTDELLDAFKEMTLLELSDFVKKFEETFEVTAAAPVAVAAAGAAPAGAAVEAAEEQSEFDVI	681
vaccine-2	LEAAGDKKIGVIKVVREIVSGLGLKEAKDLVDGAPKPLLEKVAKEAADEAKAKLEAAGATVTVK EAAAK AK	
(EV-2)	FVAAWTLKAAAGGGSMVNVISGPKGGGSILLPNKSGKGGGSGISFHPKLRGGGSSTHNTPVYKGGGSATQV	
	EQHHRGGGSSGYYSTTIRGGGSTVLDHILQKGGGSVVFSTSDGKGGGSQTNAMVTLRGPGPGQKTYSFDST	
	TAAGPGPGKTYSFDSTTAAIGPGPGWLPLGVADQKTYGPGPGTPQFLLQLNETIGPGPGPQFLLQLNETIYG	
	PGPGFLLQLNETIYTSGPGPGSFLLMLCLHHAYGPGPGFLLMLCLHHAYQGPGPGVVFSTSDGKEYTKKRS	
	NSTIARGGNSNTGFLTPESVNGDTPSNPLRPIADDTIDHASHTPGSV KK NKSGKKGNSADLTSPEK KK KKVTS	
	KNGQP KK NGVATDVPSATKRWGFRSGVPPKVVNYEAGEWAE KK KKPDGSECLPAAPDGIRG KK NGAKNIS	
	GQSPARTSSDPGTNTTTEDH KK AMPEEETTEANA KK APLTDNDRRNEPSGSTSPRML KK VVFSTSDGKEYTY	
	PDSLEEEYPPWLTEKEAMNE KK AKFVAAWTLKAAA GGGS	
Ebola	EAAAK MAENPNIDDLPAPLLAALGAADLALATVNDLIANLRERAEETRAETRTRVEERRARLTKFQEDLPEQ	710
vaccine-3	FIELRDKFTTEELRKAAEGYLEAATNRYNELVERGEAALQRLRSQTAFEDASARAEGYVDQAVELTQEALGT	
(EV-3)	VASQTRAVGERAAKLVGIEL EAAAK AKFVAAWTLKAAA GGGS MVNVISGPK GGGS ILLPNKSGK GGGS GIS	
	FHPKLRGGGSSTHNTPVYKGGGSATQVEQHHRGGGSSGYYSTTIRGGGSTVLDHILQKGGGSVVFSTSDGK	
	GGGSQTNAMVTLRGPGPGQKTYSFDSTTAAGPGPGKTYSFDSTTAAIGPGPGWLPLGVADQKTYGPGPGT	
	PQFLLQLNETIGPGPGPQFLLQLNETIYGPGPGFLLQLNETIYTSGPGPGSFLLMLCLHHAYGPGPGFLLMLC	

LHHAYQ GPGPG VVFSTSDGKEYT KK RSNSTIARGGNSNTGFLTPESVNGDTPSNPLRPIADDTIDHASHTPGS	
V KK NKSGKKGNSADLTSPEK KK KKVTSKNGQP KK NGVATDVPSATKRWGFRSGVPPKVVNYEAGEWAE K	
K KKPDGSECLPAAPDGIRG KK NGAKNISGQSPARTSSDPGTNTTTEDH KK AMPEEETTEANA KK APLTDNDR	
RNEPSGSTSPRML KK VVFSTSDGKEYTYPDSLEEEYPPWLTEKEAMNE KK AKFVAAWTLKAAA GGGS	

3.8. Antigenicity, Allergenicity and Physicochemical Property Analysis of the Vaccine

Constructs

The antigenicity prediction of the three vaccine constructs showed that all of the vaccine constructs were potential antigens. However, since all of the vaccine constructs were non-allergen, they are safe to use. In the physicochemical property analysis, the number of amino acids, molecular weight, extinction coefficient (in M⁻¹ cm⁻¹), theoretical pI, half-life, instability index, aliphatic index and GRAVY were determined. All the vaccines quite similar theoretical pI and ext. coefficient (EV-3 had the lowest value of 55475 M⁻¹ cm⁻¹) and all of them were stable. All of the vaccine constructs had the similar half-life of 1 hour in the mammalian cells. EV-2 had the highest GRAVY value of -0.504. The antigenicity, allergenicity and physicochemical property analysis of the three vaccine constructs are listed in **Table 11**.

Table 11. Antigenicity, allergenicity and physicochemical property analysis of the three vaccine constructs.

Name of	Antigenicity	Aller	Total	Molecular	Theoretical	Ext.	Est. half-	Instability	Aliphati	Grand
the	(on tumor,	genici	amin	weight	pI	coefficient	life (in	index	c index	average
vaccine	threshold	ty	0			(in M ⁻¹ cm ⁻	mammalia			of
	0.4)		acids			1)	n cell)			hydropa
										thicity
										(GRAV
										Y)
EV-1	Antigen	Non-	596	62136.84	9.62	58830	1 hour	37.98	55.70	-0.667
	(0.697)	allerg						(Stable)		
		en								
EV-2	Antigen	Non-	681	70416.13	9.01	55475	1 hour	34.14	64.13	-0.504
	(0.673)	allerg						(stable)		
		en								
EV-3	Antigen	Non-	710	74604.30	8.99	59945	1 hour	38.89	62.90	-0.627
	(0.709)	allerg						(stable)		
		en								

3.9. Secondary and Tertiary Structure Prediction of the Vaccine Constructs

The secondary structures of the three vaccine constructs were generated by two online tools, PRISPRED (http://bioinf.cs.ucl.ac.uk/psipred/) and NetTurnP v1.0 (http://www.cbs.dtu.dk/services/NetTurnP/). From the secondary structure analysis, it was analyzed that, the EV-3 had the highest percentage of the amino acids (35.2%) in the coil formation and EV-2 the highest percentage of amino acids (53.2%) in the beta-strand formation. However, EV-1 had the highest percentage of 14.5% of amino acids in the alpha-helix formation (**Figure 05** and **Table 12**).

The 3D structures of the vaccine constructs were predicted by the online server RaptorX (http://raptorx.uchicago.edu/). All the three vaccines had 5 domains and EV-1 had the lowest p-value of 4.94e-12. The homology modeling of the three dengue vaccine constructs were carried out using 5HJ3C as template from protein data bank (https://www.rcsb.org/). The results of the 3D structure analysis are listed in **Table 13** and illustrated in **Figure 06**.

Table 12. Results of the secondary structure analysis of the vaccine constructs.

Name of the	Alpha helix (percentage	Beta sheet (percentage of	Coil structure (percentage
vaccine	of amino acids)	amino acids)	of amino acids)
EV-1	19.8%	65.6%	14.5%
EV-2	27.8%	58.0%	14.2%
EV-3	35.2%	53.2%	11.5%

Table 13. Results of the tertiary structure analysis of the vaccine constructs.

Name of the vaccine	Number of the domains	p-value
EV-1	5	4.94e-12
EV-2	5	1.37e-07
EV-3	5	9.85e-12




Figure 05. The results of the secondary structure prediction of the constructed HPV-16 vaccines. Here, (a) is EV-1, (b) is EV-2, (c) is EV-3. The secondary structures were predicted using online server PRISPRED (http://bioinf.cs.ucl.ac.uk/psipred/).




Figure 06. The tertiary structures of the three Ebola vaccines. Here, (a) is the EV-1, (b) is the EV-2 and (c) is the EV-3. The tertiary structures were predicted using the online server tool RaptorX (http://raptorx.uchicago.edu/) and visualized by Discovery Studio Visualizer.

3.10. 3D Structure Refinement and Validation

The protein structures generated by the RaptorX server (http://raptorx.uchicago.edu/) were refined using 3Drefine (http://sysbio.rnet.missouri.edu/3Drefine/) and then the refined structures were validated by Ramachandran plot generated by PROCHECK server (https://servicesn.mbi.ucla.edu/PROCHECK/). The analysis showed that EV-1 vaccine had 65.0% of the amino acids in the most favored region, 31.1% of the amino acids in the additional allowed regions, 3.3% of the amino acids in the generously allowed regions and 0.7% of the amino acids in the disallowed regions. The EV-2 vaccine had 66.0% of the amino acids in the most favored region, 29.9% of the amino acids in the additional allowed regions, 3.4% of the amino acids in the generously allowed regions and 0.7% of the amino acids in the disallowed regions. The EV-3 vaccine had 72.1% of the amino acids in the most favored regions, 24.0% of the amino acids in the additional allowed regions, 2.7% of the amino acids in the generously allowed regions and 1.2% of the amino acids in the disallowed regions (**Figure 07**).




Figure 07. The Ramachandran plot analysis of the three vaccine constructs. (a) EV-1, (b) EV-2, (c) EV-3. The 3D structures of the constructed vaccines were refined using online refinement tool 3Drefine (http://sysbio.rnet.missouri.edu/3Drefine/) and validated by analyzing the Ramachandran plot, generated using the online tool PROCHECK (https://servicesn.mbi.ucla.edu/PROCHECK/).

3.11. Protein Disulfide Engineering

In protein disulfide engineering, disulfide bonds were generated for the 3D structures of the vaccine constructs. The DbD2 server identifies the pairs of amino acids that have the capability to form disulfide bonds based on the given selection criteria. In this experiment, we selected only those amino acid pairs that had bond energy value was less than 2.00 kcal/mol. The EV-1 generated 28 amino acid pairs that had the capability to form disulfide bonds. However, only 6 pairs were selected since they had bond energy less than 2.00 kcal/mol: 20 Gly and 127 Gln, 59 Val and 79 Gly, 101 Ser and 114 His, 195 Ser and 238 Pro, 292 Gly and 293 Ser, 318 His and 364 Gly. EV-2 generated 29 pairs of amino acids that had the capability to form disulfide bonds, however, only 4 pairs were selected: 60 Glu and 67 Glu, 68 Phe and Ala, 240 His and 255 Asp, 498 Val and 560 Arg. EV-3 generfated 28 pairs of amino acids capable of forming disulfide bonds and only 5 pairs of the amino acids were selected: 214 Ile and 261 Gly, 229 Asn and 293 Asn, 332 Ala and 344 Val, 438 Gly and 439 Pro, 459 Thr and 476 Val. The selected amino acid pairs formed the mutant version of the original vaccines in the DbD2 server (**Figure 08**).




Figure 08. The disulfide engineering of the three vaccine constructs, both the original (left) and mutant (right) forms are shown. Here, (a) EV-1, (b) EV-2, (c) EV-3. The disulfide engineering was conducted using the online tool DbD2 server (http://cptweb.cpt.wayne.edu/DbD2/).

3.12. Protein-Protein Docking Study

The protein-protein docking of the vaccine constructs and the MHC alleles were carried out by several online tools for enhancing the accuracy of the prediction: ClusPro 2.0 (https://cluspro.bu.edu/login.php), PatchDock (https://bioinfo3d.cs.tau.ac.il/PatchDock/php.php) and HawkDock server (http://cadd.zju.edu.cn/hawkdock/). The docked complexes that were generated by ClusPro 2.0 and PatchDock were further analyzed by PRODIGY tool of HADDOCK webserver (https://haddock.science.uu.nl/) and FireDock server (http://bioinfo3d.cs.tau.ac.il/FireDock/php.php), respectively. The PRODIGY server generated binding affinity score (in kcal/mol) and FireDock server generated the global energy of the docked complexes. However, HawkDock generated ranking scores along with the binding free energy (in Kcal/mol). The binding free energy was generated after the MM-GBSA study in the HawkDock server. The vaccine constructs were also docked with the TLR-8.

EV-1 showed the best performances in the results generate by the ClusPro 2.0 and PRODIGY server. It had the lowest binding affinity when docked against DRB3*0202 (-17.3 kcal/mol), DRB1*0101 (-19.2 kcal/mol), DRB3*0101 (-19.2 kcal/mol), DRB1*0401 (-21.5 kcal/mol), DRB1*0301 (-17.9 kcal/mol) and TLR-8 (-21.9 kcal/mol). When the docking was performed by the PatchDock server, EV-3 showed the best performances with the lowest score while docking with DRB3*0202 (-19.59), DRB5*0101 (-23.35), DRB3*0101 (-9.89) and TLR-8 (-22.21). However, EV-1 showed the best performances and lowest scores, when docked against all the selected MHC alleles by the HawkDock server and also when analyzed by the MM-GBSA study. For this reason, EV-1 should be considered as the best vaccine construct among the three vaccine constructs, since it generated the best values among the three vaccines in most of the studies (Figure 09). Table 14 lists the results of the docking study of the three Ebola vaccine constructs.

Table 14. Results of the docking study of all the vaccine constructs.

Name of	Name of the	PDB IDs	Binding	Global	HawkDock	MM-GBSA
the	Targets	of the	affinity,	energy	score (the	(binding free
vaccines		targets	ΔG (kcal		lowest	energy, in kcal
			mol ⁻¹)		score)	mol ⁻¹)
EV-1	DRB3*0202	1A6A	-17.3	-3.60	-6220.65	-58.62
	DRB5*0101	1H15	-19.8	1.34	-6003.66	-98.32
	DRB1*0101	2FSE	-19.3	-22.18	-7455.95	-126.19
	DRB3*0101	2Q6W	-19.2	8.86	-6347.92	-74.11
	DRB1*0401	2SEB	-21.5	-33.85	-5793.01	-60.95
	DRB1*0301	3C5J	-17.9	11.21	-6835.73	-69.93
	TLR8	3W3M	-21.9	-2.29	-6148.16	-66.70
EV-2	DRB3*0202	1A6A	-16.9	-18.38	-4926.81	-1.94
	DRB5*0101	1H15	-19.8	-13.53	-4935.45	-71.05
	DRB1*0101	2FSE	-19.2	-18.66	-5684.59	-52.92
	DRB3*0101	2Q6W	-18.9	-2.82	-6046.53	-42.83
	DRB1*0401	2SEB	-21.5	-40.90	-5243.99	-16.20
	DRB1*0301	3C5J	-17.5	-0.08	-4720.13	-36.24
	TLR8	3W3M	-20.7	-5.71	-5295.64	-27.63
EV-3	DRB3*0202	1A6A	-17.1	-19.59	-5205.55	-54.82
	DRB5*0101	1H15	-19.8	-23.35	-4481.78	-52.61
	DRB1*0101	2FSE	-19.3	-21.01	-5585.34	-85.44

2Q6W	-19.0	-9.89	-4905.59	-23.38
2SEB	-21.3	-10.08	-5048.95	-46.65
3C5J	-17.0	9.69	-5153.60	-47.36
3W3M	-21.2	-22.21	-5773.78	-28.08
	2SEB 3C5J	2SEB -21.3 3C5J -17.0	2SEB -21.3 -10.08 3C5J -17.0 9.69	2SEB -21.3 -10.08 -5048.95 3C5J -17.0 9.69 -5153.60




Figure 09. Figure showing the interaction between the ligand protein, EV-1 and receptor protein, TLR-8. The ligand protein is indicated by pink color and the receptor protein is indicated by green color. The visualization of the interactions of the ligands and their receptors were performed by PyMol tool.

3.13. Molecular Dynamics Simulation

Figure 10 illustrates the molecular dynamics simulation and normal mode analysis (NMA) of EV-1-TLR-8 docked complex. The deformability graphs of the complex illustrates the peaks in the graphs which represent the regions of the protein with deformability (Figure 10b). The B-factor graphs of the complexes give easy understanding and visualization of the comparison between the NMA and the PDB field of the docked complex (Figure 10c). The eigenvalues of the complex is illustrated in Figure 10d. EV-1 and TLR8 docked complex generated eigenvalue of 2.129193e-05. The variance graph indicates the individual variance by red colored bars and cumulative variance by green colored bars (Figure 10e). Figure 10f illustrates the co-variance map of the complex where the correlated motion between a pair of residues are indicated by red color, uncorrelated motion is indicated by white color and anti-correlated motion is indicated by blue color. The elastic map of the complex represents the connection between the atoms and darker gray regions indicate stiffer regions (Figure 10g) [67, 68, 69].




Figure 10. Figure displaying the results of molecular dynamics simulation study of EV-1 and TLR-8 docked complex. Here, (a) NMA mobility, (b) deformability, (c) B-factor, (d) eigenvalues, (e) variance (red color indicates individual variances and green color indicates cumulative variances), (f) co-variance map (correlated (red), uncorrelated (white) or anti-correlated (blue) motions) and (g) elastic network (darker gray regions indicate more stiffer regions).

3.14. Codon Adaptation and In Silico Cloning

For in silico cloning and plasmid construction, the protein sequences of the best selected

vaccines were adapted by the JCat server (http://www.jcat.de/).

Since the EV-1 protein had 596 amino acids, after reverse translation, the number nucleotides of

the probable DNA sequence of EV-1 would be 1788. The codon adaptation index (CAI) value of

0.943 of EV-1 indicated that the DNA sequences contained higher proportion of the codons that

are most likely to be present and used in the cellular machinery of the target organism E. coli strain

K12 (codon biasness). For this reason, the production of the EV-1 vaccine would be carried out

efficiently [73, 74]. The GC content of the improved sequence was 50.73%. The predicted DNA

sequence of EV-1 was inserted into the pET-19b vector plasmid between the SgrAI and SphI

restriction sites. Since the DNA sequence did not have restriction sites for SgrAI and SphI

restriction enzymes, SgrA1 and SphI restriction sites were conjugated at the N-terminal and C-

terminal sites, respectively, before inserting the sequence into the plasmid pET-19b vector. The

newly constructed cloned plasmid would be 7360 base pair long, including the constructed DNA

sequence of the EV-1 vaccine (the EV-1 vaccine DNA sequence also included the SgrAI and SphI

57

restriction sites) (Figure 11 and Figure 12).




Figure 11. Figure showing the codon adaptation graphs of the EV-1 vaccine. The codon adaptation of the vaccine constructs were carried out using the server JCat (https://jcatbeauty.com/).




Figure 12. In silico restriction cloning of the EV-1 vaccine sequence in the pET-19b plasmid between the SgrAI and SphI restriction enzyme sites. The red colored marked sites contain the DNA inserts of the vaccines. The cloning was carried out using the SnapGene tool. The two newly constructed plasmids can be inserted into *E. coli* strain K12 for efficient vaccine production.

4. Discussion

Vaccine is one of the most important and widely produced pharmaceutical products. However, the development and production of vaccines, is a costly process. Sometimes, it takes many years to develop a proper vaccine candidate against a particular pathogen. In modern times, various methods and tools of bioinformatics, immunoinformatics and reverse vaccinomics are used for vaccine development, which save time and cost of the vaccine development process [75].

The current study was carried out to design possible vaccines against the Zaire Ebola virus, strain-Mayinga 76. The strain of the Ebola virus, against which the vaccines were designed, was selected by reviewing the NCBI database (https://www.ncbi.nlm.nih.gov/). Three proteins of the Zaire Ebola virus strain- Mayinga 76, were selected as the potential targets for the vaccines: matrix protein VP40, envelope glycoprotein and nucleoprotein. The matrix protein VP40 of Ebola virus plays very important roles in the life cycle of a virus, regulating the regulating the viral transcription, virion assembly and budding of viruses from the infected cells [76]. Moreover, the envelope glycoprotein of the Ebola virus mediates the proper viral attachment and entry into the target cell [77]. Studies have also revealed the essential role of nucleoprotein in the replication of Ebola virus [78]. Since these three proteins play very important role in the infection, proliferation and life cycle of the Ebola virus, these proteins could be potential target for vaccine development, thus inhibiting the viral reproduction and infection.

The three protein sequences were retrieved from the UniProt (https://www.uniprot.org/) database. The envelope glycoprotein had accession number: Q05320, matrix protein VP40 had accession number: Q05128 and nucleoprotein had accession number: P18272. Various physicochemical properties like number of amino acids, molecular weight, theoretical pI, extinction co-efficient, instability index, aliphatic index, GRAVY were determined by ProtParam

(https://web.expasy.org/protparam/) server. The envelope glycoprotein showed the best performances in the physicochemical property analysis. Envelope glycoprotein is the only stable protein among the three selected proteins of the virus, among the three viral proteins.

However, all the proteins were found to be quite antigenic in the bacteria, parasitic and tumor model, where 0.4 threshold was kept. Matrix protein VP40 generated 0.5692 (bacteria), 0.4598 (tumor), 0.5496 (parasite) in the antigenic test. Envelope glycoprotein showed 0.5852 (bacteria), 0.4933 (tumor), 0.5364 (parasite) scores and nucleoprotein generated 0.5315 (bacteria), 0.5442 (tumor), 0.4692 (parasite) scores in the antigenicity test.

The main cells that function in immunity are the T lymphocytic cell and B lymphocytic cell. After recognized by an antigen presenting cell (like macrophage, dendritic cell etc.), the antigen is presented through the MHC class-II molecule present on the surface of the antigen presenting cell, to the helper T cell. Since, the helper T cell contains CD4+ molecule on its surface, it is also known as CD4+ T cell. After activated by the antigen presenting cell, the T-helper cell then activates the B cell and cause the production of memory B cell and antibody producing plasma B cell. The plasma B cell produce a large number of antibodies and the memory B cell functions as the immunological memory. However, T-helper cell also activates macrophage and CD8+ cytotoxic T cell which destroy the target antigen [79, 80, 81, 82, 83].

The possible T cell and B cell epitopes of the selected viral proteins were determined by the IEDB (https://www.iedb.org/) server. These epitopes should be able to induce strong immune response against the vaccines. The IEDB server generates and ranks the T cell epitopes based on their antigenicity scores (AS) and percentile scores. Based on analyzing AS and percentile scores, ten of the top twenty MHC class-I epitopes or CTL epitopes were selected randomly for further analysis. On the other hand, MHC class-II epitopes or HTL epitopes were also selected based on

analyzing the AS or percentile scores. Like the MHC class-I epitopes, ten MHC class-II epitopes were randomly selected from the top twenty epitopes. However, the B cell epitopes that had sequence length of 10 amino acids or over 10 amino acids, were selected for further analysis. The transmemebrane topology of the epitopes were determined to identify whether the epitopes would be present inside or outside of the cell membrane. The transmembrane topology of the selected epitopes were performed using TMHMM v2.0 server (http://www.cbs.dtu.dk/services/TMHMM/). Antigenicity can be defined as the ability of a foreign substance to act as antigen and activate and stimulate the T cell and B cell responses, through their antigenic determinant portion or epitope [84]. The allergenicity of a substance refers to the ability of that substance to act as allergen and induce potential allergic reactions within the body [85]. When designing a vaccine, epitopes of a protein that remain conserved across various strain, are given much priority than genomic regions that are highly variable because the conserved epitopes of protein(s) provide broader protection across various strains and species [86]. When selecting the best epitopes for vaccine construction, some criteria were maintained: the epitopes should be highly antigenic, so that they can induce high antigenic response, the epitopes should be non-allergenic in nature, for this reason, they would not be able to induce any allergenic reaction in an individual and the epitopes should be non-toxic. The epitopes with 100% conservancy and over 50% minimum identity were selected for vaccine construction, so that, the conserved epitopes would be able to provide protection against various strains. The conservancy analysis was carried out using Zaire Ebola virus strains- Gabon 94 and Kikwit 95, for comparison. Since the selected epitopes were 100% conserved across these strains, for this reason, the vaccine that was constructed for ebola virus strain- Mayinga 76, should provide immunity against the Gabon 94 and Kikwit 95 strains too. Moreover, the cluster analysis of the MHC class-I alleles and MHC class-II alleles were also carried out to determine their relationship with each other and cluster them functionally based on their predicted binding specificity [87].

In the next step, the protein-peptide docking was carried out between the epitopes and the MHC alleles. The MHC class-I epitopes were docked with the MHC class-I allele (PDB ID: 5WJL) and the MHC class-II epitopes were docked with the MHC class-II allele (PDB ID: 5JLZ). The proteinpeptide docking was performed to determine the ability of the epitopes to bind with their respective MHC allele. The 3D structures of the selected epitopes were generated by PEP-FOLD3 (http://bioserv.rpbs.univ-paris-diderot.fr/services/PEP-FOLD3/) server. After that, the generated 3D structures were docked with HLA-A*11-01 allele (PDB ID: 5WJL) and HLA DRB1*04-01 (PDB ID: 5JLZ) using PatchDock (https://bioinfo3d.cs.tau.ac.il/PatchDock/php.php) server and refined by FireDock server (http://bioinfo3d.cs.tau.ac.il/FireDock/php.php). GISFHPKLR showed the best result with the lowest global energy of -31.68 among the MHC class-I epitopes of matrix protein VP40. SGYYSTTIR generated the lowest and best global energy score of -42.87 among the MHC class-I epitopes of envelope glycoprotein. QTNAMVTLR generated the best global energy score of -45.40 of the MHC class-I epitopes of nucleoprotein. On the other hand, among the MHC class-II epitopes of matrix protein VP40, KTYSFDSTTAAI generated the best global energy score of -24.32. TPQFLLQLNETI generated the lowest global energy of -2.80 among the MHC class-II epitopes of envelope glycoprotein. Moreover, among the MHC class-II epitopes of nucleoprotein, VVFSTSDGKEYT generated the lowest global energy of -12.06.

After the successful protein-peptide docking, the vaccine construction step was carried out. Three different vaccines were constructed and the three vaccines differed from each other only in their adjuvant sequence. The three vaccines were designated as EV-1, EV-2 and EV-3. EV-1 had beta

defensing adjuvant, EV-2 had L7/L12 ribosomal protein as adjuvant and EV-3 had HABA protein as adjuvant. The PADRE sequence was added after the adjuvant sequence and then the CTL, HTL and BCL epitopes were conjugated sequentially. EAAAK, GGGS, GPGPG, KK linkers were used to conjugate the epitopes as well as the adjuvants and PADRE sequence.

After the vaccine construction was performed, the antigenicity, allergenicity and physicochemical property analysis were carried out. All the vaccine constructs were proved to be potential antigenic, however, they were also non-allergenic, for this reason, they should not cause any allergenic reaction within the body. The instability index of a compound refers to the probability of the compound to be stable. IF a compound had instability index of over 40, then the compound is considered to be unstable [88]. The extinction coefficient refers to the amount of light, that is absorbed by a compound at a certain wavelength [89, 90]. EV-3 had the highest extinction coefficient of 59945 M⁻¹ cm⁻¹. The aliphatic index of a protein corresponds to the relative volume occupied by the aliphatic amino acids in the side chains like alanine, valine etc. [91]. EV-2 had the highest aliphatic index among the vaccine constructs. Since all the vaccine constructs had instability index of less than 40, for this reason, all of them were considered as stable compounds. All the three vaccine constructs had the similar half-life of 1 hour in the mammalian cell culture and all of them were stable. All of the constructs had quite similar theoretical pI. Quite similar performances were observed by the three vaccine constructs in the physicochemical property analysis.

The secondary structures of the vaccine constructs were generated by two online servers, PRISPRED (http://bioinf.cs.ucl.ac.uk/psipred/) and NetTurnP v1.0 (http://www.cbs.dtu.dk/services/NetTurnP/) and the 3D structures were generated by the server RaptorX (http://raptorx.uchicago.edu/) server. EV-3 had the highest percentage of amino acids in

the alpha-helix conformation (35.2%). EV-1 had the highest percentage of amino acids in the beta-

sheet conformation with 65.6% of the amino acids in the beta-sheet formation. EV-3 also had the

lowest percentage of amino acids (11.5%) in the coil structure of the protein. All the vaccine

constructs had 5 domains and EV-2 had the highest p-value of 1.37e-07, determined by the

RaptorX server.

In the next step, the 3D structures were refined by online tool 3D refine

(http://sysbio.rnet.missouri.edu/3Drefine/) and validated by PROCHECK

(https://servicesn.mbi.ucla.edu/PROCHECK/) server. EV-3 showed the best performances in the

validation experiment with 72.1% of the amino acids in the most favored regions and 24.0% of the

amino acids in the additional allowed regions. Moreover, EV-3 had 2.7% of the amino acids in the

generously allowed regions and 1.2% of the amino acids in the disallowed regions. After validation

of the 3D protein structures, the disulfide engineering of the vaccine constructs were performed

using Disulfide by Design 2 v12.2 (http://cptweb.cpt.wayne.edu/DbD2/) server and the amino acid

pairs with binding energy value less than 2.0 kcal/mol, were picked up for disulfide bond

formation.

To find out the best vaccine construct, the protein-protein docking the vaccine constructs and

several MHC alleles: DRB1*0101 (PDB ID: 2FSE), DRB3*0202 (PDB ID: 1A6A), DRB5*0101

(PDB ID: 1H15), DRB3*0101 (PDB ID: 2Q6W), DRB1*0401 (PDB ID: 2SEB), and DRB1*0301

(PDB ID: 3C5J) were conducted. The constructed vaccines were also docked against TLR-8 (PDB

ID: 3W3M). The aim of the docking experiment is to find out the best vaccine construct among

the constructed vaccines. For enhancing the accuracy of our prediction, three different online

65

ClusPro 2.0 (https://cluspro.bu.edu/login.php), PatchDock servers, (https://bioinfo3d.cs.tau.ac.il/PatchDock/php.php) HawkDock and server (http://cadd.zju.edu.cn/hawkdock/) were used for the docking study. The results of the ClusPro 2.0 and PatchDock were refined and analyzed by PRODIGY tool of HADDOCK webserver (https://haddock.science.uu.nl/) **FireDock** and server (http://bioinfo3d.cs.tau.ac.il/FireDock/php.php), respectively. EV-1 showed the best and excellent performances in the results generated by HADDOCK and HawkDock servers as well as in the MM-GBSA study. For this reason, EV-1 was considered the best vaccine construct which was selected for further analysis.

The molecular dynamics simulation study was carried out using the docked TLR-8 and EV-1 complex using the online tool iMODS (http://imods.chaconlab.org/). The complex showed quite good results in the molecular dynamics simulation study. The study showed that the complex had quite lesser chance of deformability with quite high eigenvalue of 2.129193e-05. The deformability graph (Figure 10b) also confirmed that the location of the hinges in the structures were not quite significant and the complex is quite stable with lower degree of deforming for each individual amino acids residue. However, EV-1 had good number of correlated amino acids (marked by red color) and also showed a large number stiffer regions (marked by darker gray color) (Figure 10f, Figure 10g, Figure 10f and Figure 10g). Nevertheless, it can be concluded that, the complex showed good results in the molecular dynamics simulation study.

Finally, the designed EV-1 vaccine was adapted for in silico cloning. After reverse transcribed, the codon adaptation was carried for cloning in to *E. coli* strain K12. After codon adaptation, the CAI

value of 0.943 was obtained, which supported that, the codon adaptation was carried out perfectly and the DNA sequence contained the codons that are most likely used by the *E. coli* cells. The vaccine DNA sequence was inserted into the SgrAI and SphI restriction sites of the pET-19b plasmid vector for efficient expression and production of the desired vaccine, EV-1 in *E. coli* cells. This insertion produced 7360 base pair long plasmid. The plasmid could be used for producing EV-1 by inserting into the *E. coli* cells. However, more in vitro and in vivo studies should be conducted to finally confirm the safety and efficacy of the predicted best considered vaccines. Moreover, since other vaccines also showed quite good results, they can also be tested to finally confirm the best vaccines among the predicted three vaccines.

5. Conclusion

Ebola virus disease or EVD is a type of haemorrhagic fever that is caused by the infection of Ebola virus. With the high mortality rate, Ebola can be considered as one of the fatal viruses in the world. However, no vaccines are yet discovered with satisfactory results, to control the outbreak of Ebola. In this study, a possible subunit vaccine to fight against Ebola was designed using various tools of bioinformatics, immunoinformatics and vaccinomics. Bioinformatics and related technologies are heavily used in drug design and development since these technologies reduce the time and cost of drug R&D processes. In this study, first the potential proteins of the viral structure are identified. Next, the potential epitopes were identified through robust processes and these epitopes were used for vaccine construction. Three possible vaccines were constructed and by conducting the docking experiments, one best vaccine construct was identified. Later, the molecular dynamics simulation study and codon adaptation as well as in silico cloning were performed. However, wet lab researches should be carried out on the findings of this experiment to finally confirm the safety,

efficacy and potentiality of the vaccine constructs. Hopefully, this research will raise interests among the scientists of the respective field.

6. Acknowledgements

Authors are thankful to Swift Integrity Computational Lab, Dhaka, Bangladesh, a virtual platform of young researchers, for providing the tools.

7. Conflict of interest

Md. Asad Ullah declares that he has no conflict of interest. Bishajit Sarkar declares that he has no conflict of interest. Syed Sajidul Islam declares that he has no conflict of interest.

8. References

[1] Nabel GJ, Yang ZY, Sullivan N, Sanchez A, inventors; US Department of Health, Human Services (HHS), assignee. Development of a preventive vaccine for filovirus infection in primates. United States patent US 8,124,592. 2012.

[2] Sanchez A, Trappier SG, Mahy BW, Peters CJ, Nichol ST. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc Natl Acad Sci 1996;16;93:3602-7. doi.org/10.1073/pnas.93.8.3602

- [3] Pourrut, X., Kumulungui, B., Wittmann, T., Moussavou, G., Délicat, A., Yaba, P., ... Leroy, E. M. (2005). The natural history of Ebola virus in Africa. Microbes and Infection, 7(7-8), 1005–1014. doi:10.1016/j.micinf.2005.04.006
- [4] Leroy EM, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, Yaba P, Délicat A, Paweska JT, Gonzalez JP, Swanepoel R. Fruit bats as reservoirs of Ebola virus. Nature 2005;438:575. doi:10.1038/438575a
- [5] Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000;408:605. doi:10.1038/35046108
- [6] Kiley MP, Bowen ET, Eddy GA, Isaäcson M, Johnson KM, McCormick JB, Murphy FA, Pattyn SR, Peters D, Prozesky OW, Regnery RL. Filoviridae: a taxonomic home for Marburg and Ebola viruses?. Intervirology 1982;18:24-32. doi.org/10.1159/000149300
- [7] Feldmann H, Geisbert TW. Ebola haemorrhagic fever. The Lancet 2011;377:849-62. doi.org/10.1016/S0140-6736(10)60667-8
- [8] Volchkov V, Volchkova V, Eckel C, Klenk HD, Bouloy M, LeGuenno B, Feldmann H. Emergence of subtype Zaire Ebola virus in Gabon. Virology 1997;232:139-44. doi.org/10.1006/viro.1997.8529
- [9] Leroy EM, Baize S, Volchkov VE, Fisher-Hoch SP, Georges-Courbot MC, Lansoud-Soukate J, Capron M, Debre P, Georges AJ, McCormick JB. Human asymptomatic Ebola infection and strong inflammatory response. The Lancet 2000;355:2210-5. doi.org/10.1016/S0140-6736(00)02405-3

- [10] Wamala JF, Lukwago L, Malimbo M, Nguku P, Yoti Z, Musenero M, Amone J, Mbabazi W, Nanyunja M, Zaramba S, Opio A. Ebola hemorrhagic fever associated with novel virus strain, Uganda, 2007–2008. Emerg Infect Dis 2010;16:1087. doi: 10.3201/eid1607.091525
- [11] World Health Organization, 2014. Experimental Ebola Vaccines: WHO Consultation on Ebola Vaccines.
- [12] Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Hu Z, Muñoz P, Moon JE, Ruck RC, Bennett JW, Twomey PS. A recombinant vesicular stomatitis virus Ebola vaccine. N Engl J Med 2017;376:330-41. DOI: 10.1056/NEJMoa1414216
- [13] Kanapathipillai R, Henao Restrepo AM, Fast P, Wood D, Dye C, Kieny MP, Moorthy V. Ebola vaccine—an urgent international priority. N Engl J Med 2014;371:2249-51. DOI: 10.1056/NEJMp1412166
- [14] Chong, L.C. and Khan, A.M., 2019. Vaccine Target Discovery.
- [15] Doytchinova IA, Flower DR. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinformatics 2007a;8:4. doi.org/10.1186/1471-2105-8-4
- [16] Doytchinova IA, Flower DR. Identifying candidate subunit vaccines using an alignment-independent method based on principal amino acid properties. Vaccine 2007b;25:856-66. doi.org/10.1016/j.vaccine.2006.09.032
- [17] Doytchinova IA, Flower DR. Bioinformatic approach for identifying parasite and fungal candidate subunit vaccines. Open Vaccine J 2008;1:4.

- [18] Gasteiger E, Hoogland C, Gattiker A, Wilkins MR, Appel RD, Bairoch A. Protein identification and analysis tools on the ExPASy server. In The proteomics protocols handbook 2005;571-607. Humana press. doi.org/10.1385/1-59259-890-0:571
- [19] Vita R, Mahajan S, Overton JA, Dhanda SK, Martini S, Cantrell JR, Wheeler DK, Sette A, Peters B. The immune epitope database (IEDB): 2018 update. Nucleic Acids Res 2018;47:D339-43. doi.org/10.1093/nar/gky1006
- [20] Möller S, Croning MD, Apweiler R. Evaluation of methods for the prediction of membrane spanning regions. Bioinformatics 2001;17:646-53. doi.org/10.1093/bioinformatics/17.7.646
- [21] Dimitrov I, Bangov I, Flower DR, Doytchinova I. AllerTOP v. 2—a server for in silico prediction of allergens. J Mol Model 2014;20:2278. doi.org/10.1007/s00894-014-2278-5
- [22] Dimitrov I, Naneva L, Doytchinova I, Bangov I. AllergenFP: allergenicity prediction by descriptor fingerprints. Bioinformatics 2013;30:846-51. doi.org/10.1093/bioinformatics/btt619
- [23] Thomsen M, Lundegaard C, Buus S, Lund O, Nielsen M. MHCcluster, a method for functional clustering of MHC molecules. Immunogenetics 2013;65:655-65. doi.org/10.1007/s00251-013-0714-9
- [24] Lamiable A, Thévenet P, Rey J, Vavrusa M, Derreumaux P, Tufféry P. PEP-FOLD3: faster de novo structure prediction for linear peptides in solution and in complex. Nucleic Acids Res 2016;44:W449-54. doi.org/10.1093/nar/gkw329
- [25] Shen Y, Maupetit J, Derreumaux P, Tufféry P. Improved PEP-FOLD approach for peptide and miniprotein structure prediction. J Chem Theory Comput 2014;10:4745-58. doi.org/10.1021/ct500592m

- [26] Thevenet P, Shen Y, Maupetit J, Guyon F, Derreumaux P, Tuffery P. PEP-FOLD: an updated de novo structure prediction server for both linear and disulfide bonded cyclic peptides. Nucleic Acids Res 2012;40:W288-93. doi.org/10.1093/nar/gks419
- [27] Duhovny D, Nussinov R, Wolfson HJ. Efficient unbound docking of rigid molecules. InInternational workshop on algorithms in bioinformatics 2002 Sep 17 (pp. 185-200). Springer, Berlin, Heidelberg. doi.org/10.1007/3-540-45784-4_14
- [28] Schneidman-Duhovny D, Inbar Y, Nussinov R, Wolfson HJ. PatchDock and SymmDock: servers for rigid and symmetric docking. Nucleic Acids Res 2005;33:W363-7. doi.org/10.1093/nar/gki481
- [29] Gujjula KR. Prediction and comparison of hiv-1 protease inhibitor binding energies by various molecular docking methods (Doctoral dissertation).
- [30] Atapour A, Mokarram P, MostafaviPour Z, Hosseini SY, Ghasemi Y, Mohammadi S, Nezafat N. Designing a fusion protein vaccine against HCV: an in silico approach. Int J Pept Res Ther 2019;25:861-72. doi.org/10.1007/s10989-018-9735-4
- [31] Rana A, Akhter Y. A multi-subunit based, thermodynamically stable model vaccine using combined immunoinformatics and protein structure based approach. Immunobiology 2016;221:544-57. doi.org/10.1016/j.imbio.2015.12.004
- [32] Hancock RE, Nijnik A, Philpott DJ. Modulating immunity as a therapy for bacterial infections. Nat. Rev. Microbiol 2012;10:243. doi.org/10.1038/nrmicro2745
- [33] Toussi DN, Massari P. Immune adjuvant effect of molecularly-defined toll-like receptor ligands. Vaccines 2014;2:323-53. doi.org/10.3390/vaccines2020323

- [34] Funderburg N, Lederman MM, Feng Z, Drage MG, Jadlowsky J, Harding CV, Weinberg A, Sieg SF. Human β-defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2. Proc Natl Acad Sci 2007;104:18631-5. doi.org/10.1073/pnas.0702130104
- [35] Lee SJ, Shin SJ, Lee MH, Lee MG, Kang TH, Park WS, Soh BY, Park JH, Shin YK, Kim HW, Yun CH. A potential protein adjuvant derived from Mycobacterium tuberculosis Rv0652 enhances dendritic cells-based tumor immunotherapy. PloS one 2014;9:e104351. doi.org/10.1371/journal.pone.0104351
- [36] Hajighahramani N, Nezafat N, Eslami M, Negahdaripour M, Rahmatabadi SS, Ghasemi Y. Immunoinformatics analysis and in silico designing of a novel multi-epitope peptide vaccine against Staphylococcus aureus. Infect Genet Evol 2017;48:83-94. doi.org/10.1016/j.meegid.2016.12.010
- [37] Pandey RK, Sundar S, Prajapati VK. Differential expression of miRNA regulates T cell differentiation and plasticity during visceral leishmaniasis infection. Front Microbiol 2016;7:206. doi.org/10.3389/fmicb.2016.00206
- [38] Wu CY, Monie A, Pang X, Hung CF, Wu TC. Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation. J Biomed Sci 2010;17:88. doi.org/10.1186/1423-0127-17-88
- [39] Saha S, Raghava GP. AlgPred: prediction of allergenic proteins and mapping of IgE epitopes. Nucleic Acids Res 2006;34:W202-9. doi.org/10.1093/nar/gkl343
- [40] Buchan DW, Jones DT. The PSIPRED protein analysis workbench: 20 years on. Nucleic Acids Res 2019;47:W402-7. doi.org/10.1093/nar/gkz297

- [41] Jones DT. Protein secondary structure prediction based on position-specific scoring matrices. J Mol Biol 1999;292:195-202. doi.org/10.1006/jmbi.1999.3091
- [42] Petersen B, Lundegaard C, Petersen TN. NetTurnP–neural network prediction of beta-turns by use of evolutionary information and predicted protein sequence features. PLoS One 2010;5:e15079. doi.org/10.1371/journal.pone.0015079
- [43] Källberg M, Wang H, Wang S, Peng J, Wang Z, Lu H, Xu J. Template-based protein structure modeling using the RaptorX web server. Nat Protoc 2012;7:1511. doi.org/10.1038/nprot.2012.085
- [44] Ma J, Wang S, Zhao F, Xu J. Protein threading using context-specific alignment potential. Bioinformatics 2013;29:i257-65. doi.org/10.1093/bioinformatics/btt210
- [45] Peng J, Xu J. RaptorX: exploiting structure information for protein alignment by statistical inference. Proteins: Struct, Funct, Bioinf 2011;79:161-71. doi.org/10.1002/prot.23175
- [46] Bhattacharya D, Nowotny J, Cao R, Cheng J. 3Drefine: an interactive web server for efficient protein structure refinement. Nucleic Acids Res 2016;44:W406-9. doi.org/10.1093/nar/gkw336
- [47] Laskowski RA, MacArthur MW, Thornton JM. PROCHECK: validation of protein-structure coordinates. Int Tab Crystallography 2006;F:722-725.
- [48] Morris AL, MacArthur MW, Hutchinson EG, Thornton JM. Stereochemical quality of protein structure coordinates. Proteins: Struct, Funct, Bioinf 1992;12:345-64. doi.org/10.1002/prot.340120407
- [49] Craig DB, Dombkowski AA. Disulfide by Design 2.0: a web-based tool for disulfide engineering in proteins. BMC Bioinformatics 2013;14:346. doi.org/10.1186/1471-2105-14-346

- [50] Stern LJ, Calvo-Calle JM. HLA-DR: molecular insights and vaccine design. Curr Pharm Des 2009;15:3249-61.
- [51] Thompson JM, Iwasaki A. Toll-like receptors regulation of viral infection and disease. Adv. Drug Deliv Rev 2008;60:786-94. doi.org/10.1016/j.addr.2007.11.003
- [52] Lester SN, Li K. Toll-like receptors in antiviral innate immunity. J Mol Biol 2014;426:1246-64. doi.org/10.1016/j.jmb.2013.11.024
- [53] Regnery RL, Johnson KM, Kiley MP. Virion nucleic acid of Ebola virus. J Virol 1980;36:465-469.
- [54] Vajda S, Yueh C, Beglov D, Bohnuud T, Mottarella SE, Xia B, Hall DR, Kozakov D. New additions to the C lus P ro server motivated by CAPRI. Proteins: Struct, Funct, Bioinf 2017;85:435-44. doi.org/10.1002/prot.25219
- [55] Kozakov D, Hall DR, Xia B, Porter KA, Padhorny D, Yueh C, Beglov D, Vajda S. The ClusPro web server for protein—protein docking. Nat Protoc 2017;12:255. doi.org/10.1038/nprot.2016.169
- [56] Kozakov D, Beglov D, Bohnuud T, Mottarella SE, Xia B, Hall DR, Vajda S. How good is automated protein docking?. Proteins: Struct, Funct, Bioinf 2013;81:2159-66. doi.org/10.1002/prot.24403
- [57] Vangone A, Bonvin AM. Contacts-based prediction of binding affinity in protein—protein complexes. Elife 2015;4:e07454.

- [58] Xue LC, Rodrigues JP, Kastritis PL, Bonvin AM, Vangone A. PRODIGY: a web server for predicting the binding affinity of protein–protein complexes. Bioinformatics 2016;32:3676-8. doi.org/10.1093/bioinformatics/btw514
- [59] Yuriev E, Ramsland PA. Latest developments in molecular docking: 2010–2011 in review. J Mo Recog 2013;26:215-39. doi.org/10.1002/jmr.2266
- [60] Weng G, Wang E, Wang Z, Liu H, Zhu F, Li D, Hou T. HawkDock: a web server to predict and analyze the protein–protein complex based on computational docking and MM/GBSA. Nucleic Acids Res 2019. doi.org/10.1093/nar/gkz397
- [61] Hou T, Wang J, Li Y, Wang W. Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. J Chem Inf Model 2010;51:69-82.
- [62] Feng T, Chen F, Kang Y, Sun H, Liu H, Li D, Zhu F, Hou T. HawkRank: a new scoring function for protein–protein docking based on weighted energy terms. J Cheminformatics 2017;9:66. doi.org/10.1186/s13321-017-0254-7
- [63] Sun H, Li Y, Tian S, Xu L, Hou T. Assessing the performance of MM/PBSA and MM/GBSA methods. 4. Accuracies of MM/PBSA and MM/GBSA methodologies evaluated by various simulation protocols using PDBbind data set. Phys Chem Chem Phys 2014;16:16719-29. DOI: 10.1039/C4CP01388C
- [64] The *PyMOL* Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC.
- [65] Awan F, Obaid A, Ikram A, Janjua H. Mutation-structure-function relationship based integrated strategy reveals the potential impact of deleterious missense mutations in autophagy

related proteins on hepatocellular carcinoma (HCC): A comprehensive informatics approach. Int J Mol Sci 2017;18:139. doi.org/10.3390/ijms18010139

- [66] Prabhakar PK, Srivastava A, Rao KK, Balaji PV. Monomerization alters the dynamics of the lid region in Campylobacter jejuni CstII: an MD simulation study. J Biomol Struct Dyn 2016;34:778-91. doi.org/10.1080/07391102.2015.1054430
- [67] López-Blanco JR, Aliaga JI, Quintana-Ortí ES, Chacón P. iMODS: internal coordinates normal mode analysis server. Nucleic Acids Res 2014;42:W271-6. doi.org/10.1093/nar/gku339
- [68] Lopéz-Blanco JR, Garzón JI, Chacón P. iMod: multipurpose normal mode analysis in internal coordinates. Bioinformatics 2011;27:2843-50. doi.org/10.1093/bioinformatics/btr497
- [69] Kovacs JA, Chacón P, Abagyan R. Predictions of protein flexibility: first-order measures. Proteins: Struct, Funct, Bioinf 2004;56:661-8. doi.org/10.1002/prot.20151
- [70] Grote A, Hiller K, Scheer M, Münch R, Nörtemann B, Hempel DC, Jahn D. JCat: a novel tool to adapt codon usage of a target gene to its potential expression host. Nucleic Acids Res 2005;33:W526-31. doi.org/10.1093/nar/gki376
- [71] Angov E. Codon usage: nature's roadmap to expression and folding of proteins. Biotechnol J 2011;6:650-9. doi.org/10.1002/biot.201000332
- [72] Solanki V, Tiwari V. Subtractive proteomics to identify novel drug targets and reverse vaccinology for the development of chimeric vaccine against Acinetobacter baumannii. Sci Rep 2018;8:9044. doi.org/10.1038/s41598-018-26689-7
- [73] Carbone A, Zinovyev A, Képes F. Codon adaptation index as a measure of dominating codon bias. Bioinformatics 2003;19:2005-15. doi.org/10.1093/bioinformatics/btg272

- [74] Sharp PM, Li WH. The codon adaptation index-a measure of directional synonymous codon usage bias, and its potential applications. Nucleic Acids Res 1987;15:1281-95. doi.org/10.1093/nar/15.3.1281
- [75] María RA, Arturo CV, Alicia JA, Paulina ML, Gerardo AO. The impact of bioinformatics on vaccine design and development. InTech, Rijeka, Croatia; 2017.
- [76] Madara JJ, Han Z, Ruthel G, Freedman BD, Harty RN. The multifunctional Ebola virus VP40 matrix protein is a promising therapeutic target. Future Virol 2015;10:537-46. doi.org/10.2217/fvl.15.6
- [77] Martinez O, Ndungo E, Tantral L, Miller EH, Leung LW, Chandran K, Basler CF. A mutation in the Ebola virus envelope glycoprotein restricts viral entry in a host species-and cell-type-specific manner. J Virol. 2013;87:3324-34. doi.org/10.1128/jvi.01598-12
- [78] Watanabe S, Noda T, Kawaoka Y. Functional mapping of the nucleoprotein of Ebola virus. J Virol. 2006 Apr 15;80(8):3743-51. doi.org/10.1128/jvi.80.8.3743-3751.2006
- [79] Goerdt S, Orfanos CE. Other functions, other genes: alternative activation of antigenpresenting cells. Immunity 1999;10:137-42.
- [80] Tanchot C, Rocha B. CD8 and B cell memory: same strategy, same signals. Nat Immunol 2003;4:431. doi.org/10.1038/ni0503-431
- [81] Pavli P, Hume DA, Van De Pol E, Doe WF. Dendritic cells, the major antigen-presenting cells of the human colonic lamina propria. Immunology 1993;78:132.
- [82] Arpin C, Dechanet J, Van Kooten C, Merville P, Grouard G, Briere F, Banchereau J, Liu YJ. Generation of memory B cells and plasma cells in vitro. Science 1995;268:720-2. DOI: 10.1126/science.7537388

- [83] Cano RL, Lopera HD. Introduction to T and B lymphocytes. InAutoimmunity: From Bench to Bedside [Internet] 2013. El Rosario University Press.
- [84] Fishman JM, Wiles K, Wood KJ. The acquired immune system response to biomaterials, including both naturally occurring and synthetic biomaterials. InHost Response to Biomaterials 2015;151-187. Academic Press. doi.org/10.1016/B978-0-12-800196-7.00008-6
- [85] Andreae D, Nowak-Węgrzyn A. The Effect of Infant Allergen/Immunogen Exposure on Long-Term Health. InEarly Nutrition and Long-Term Health 2017;131-173. Woodhead Publishing. doi.org/10.1016/B978-0-08-100168-4.00006-9
- [86] Bui HH, Sidney J, Li W, Fusseder N, Sette A. Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines. BMC Bioinformatics 2007;8:361. doi.org/10.1186/1471-2105-8-361
- [87] Thomsen M, Lundegaard C, Buus S, Lund O, Nielsen M. MHCcluster, a method for functional clustering of MHC molecules. Immunogenetics 2013;65:655-65. doi.org/10.1007/s00251-013-0714-9
- [88] Guruprasad K, Reddy BB, Pandit MW. Correlation between stability of a protein and its dipeptide composition: a novel approach for predicting in vivo stability of a protein from its primary sequence. Protein Eng Des Sel 1990;4:155-61. doi.org/10.1093/protein/4.2.155
- [89] Pace CN, Vajdos F, Fee L, Grimsley G, Gray T. How to measure and predict the molar absorption coefficient of a protein. Protein Sci 1995;4:2411-23. doi.org/10.1002/pro.5560041120
- [90] Ikai A. Thermostability and aliphatic index of globular proteins. J Biochem 1980;88:1895-8.

[91] Gill SC, Von Hippel PH. Calculation of protein extinction coefficients from amino acid sequence data. Anal Biochem 1989;182:319-26. doi.org/10.1093/oxfordjournals.jbchem.a133168